dbACP: A Comprehensive Database of Anti-Cancer Peptides

2191 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00028 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 14.2% inhibition at 10-6 M
dbacp00029 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 19.7% inhibition at 10-5 M
dbacp00030 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 24.9% inhibition at 10-4 M
dbacp00031 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 30.4% inhibition at 10-3 M
dbacp00032 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 10% inhibition at 10-5 M
dbacp00033 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 8.2% inhibition at 10-4 M
dbacp00034 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 36.1% inhibition at 10-3 M
dbacp00035 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 6.5% inhibition at 10-6 M
dbacp00036 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 14% inhibition at 10-5 M
dbacp00037 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.5% inhibition at 10-4 M
dbacp00038 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 14% inhibition at 10-3 M
dbacp00039 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.8% inhibition at 10-6 M
dbacp00040 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 1.6% inhibition at 10-5 M
dbacp00041 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.4% inhibition at 10-4 M
dbacp00042 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 26.5% inhibition at 10-3 M
dbacp00043 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 12.9% inhibition at 10-6 M
dbacp00044 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 16.5% inhibition at 10-5 M
dbacp00045 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 28.1% inhibition at 10-4 M
dbacp00046 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 58.2% inhibition at 10-3 M
dbacp00047 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.5% inhibition at 10-6 M
dbacp00048 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 22.7% inhibition at 10-5 M
dbacp00049 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 18.9% inhibition at 10-4 M
dbacp00050 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 26.4% inhibition at 10-3 M
dbacp00051 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 2.4% inhibition at 10-5 M
dbacp00052 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.5% inhibition at 10-4 M
dbacp00053 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 6.2% inhibition at 10-6 M
dbacp00054 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 6.4% inhibition at 10-5 M
dbacp00055 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 8.2% inhibition at 10-4 M
dbacp00056 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 21.2% inhibition at 10-3 M
dbacp00057 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.5% inhibition at 10-6 M
dbacp00058 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 6.1% inhibition at 10-5 M
dbacp00059 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 3.1% inhibition at 10-4 M
dbacp00060 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 14.8% inhibition at 10-3 M
dbacp00061 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.9% inhibition at 10-5 M
dbacp00062 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.3% inhibition at 10-3 M
dbacp00063 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 4.9% inhibition at 10-6 M
dbacp00064 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 8.9% inhibition at 10-5 M
dbacp00065 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.4% inhibition at 10-4 M
dbacp00066 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 20.8% inhibition at 10-3 M
dbacp00067 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.5% inhibition at 10-6 M
dbacp00068 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 21.9% inhibition at 10-5 M
dbacp00069 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 11.8% inhibition at 10-4 M
dbacp00070 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 17.9% inhibition at 10-3 M
dbacp00071 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.7% inhibition at 10-6 M
dbacp00072 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 16.5% inhibition at 10-5 M
dbacp00073 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.4% inhibition at 10-4 M
dbacp00074 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 14.5% inhibition at 10-3 M
dbacp00075 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 1.1% inhibition at 10-5 M
dbacp00076 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 1.2% inhibition at 10-4 M
dbacp00077 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 17.8% inhibition at 10-3 M
dbacp00078 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 8.5% inhibition at 10-6 M
dbacp00079 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.9% inhibition at 10-5 M
dbacp00080 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 1.9% inhibition at 10-4 M
dbacp00081 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 16.2% inhibition at 10-3 M
dbacp00082 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.2% inhibition at 10-6 M
dbacp00083 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 17.1% inhibition at 10-5 M
dbacp00084 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.0% inhibition at 10-4 M
dbacp00085 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 20.5% inhibition at 10-3 M
dbacp00086 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.0% inhibition at 10-6 M
dbacp00087 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.7% inhibition at 10-5 M
dbacp00088 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.7% inhibition at 10-4 M
dbacp00089 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.3% inhibition at 10-3 M
dbacp00090 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 0.7% inhibition at 10-6 M
dbacp00091 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 8.3% inhibition at 10-5 M
dbacp00092 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 10.5% inhibition at 10-4 M
dbacp00093 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 21.8% inhibition at 10-3 M
dbacp00094 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.7% inhibition at 10-6 M
dbacp00095 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.0% inhibition at 10-5 M
dbacp00096 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.7% inhibition at 10-4 M
dbacp00097 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 18.7% inhibition at 10-3 M
dbacp00125 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 2.7% inhibition at 10-6 M
dbacp00126 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 2.0% inhibition at 10-5 M
dbacp00127 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 18.8% inhibition at 10-4 M
dbacp00128 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 26.7% inhibition at 10-3 M
dbacp00129 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.8% inhibition at 10-6 M
dbacp00130 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.3% inhibition at 10-5 M
dbacp00131 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.9% inhibition at 10-4 M
dbacp00132 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.2% inhibition at 10-3 M
dbacp00133 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.6% inhibition at 10-6 M
dbacp00134 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.9% inhibition at 10-5 M
dbacp00135 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 5.9% inhibition at 10-4 M
dbacp00136 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 17.9% inhibition at 10-3 M
dbacp00137 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.4% inhibition at 10-6 M
dbacp00138 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.4% inhibition at 10-5 M
dbacp00139 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.5% inhibition at 10-4 M
dbacp00140 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 15.7% inhibition at 10-3 M
dbacp00141 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.6% inhibition at 10-6 M
dbacp00142 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 20.4% inhibition at 10-5 M
dbacp00143 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 14.4% inhibition at 10-4 M
dbacp00144 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 23.4% inhibition at 10-3 M
dbacp00145 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 2.2% inhibition at 10-6 M
dbacp00146 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 4.2% inhibition at 10-5 M
dbacp00147 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.4% inhibition at 10-4 M
dbacp00148 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.2% inhibition at 10-3 M
dbacp00149 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 21.2% inhibition at 10-3 M
dbacp00159 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.6% inhibition at 10-6 M
dbacp00160 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.9% inhibition at 10-5 M
dbacp00161 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 12.6% inhibition at 10-4 M
dbacp00162 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 26.4% inhibition at 10-3 M
dbacp00163 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.0% inhibition at 10-6 M
dbacp00164 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.7% inhibition at 10-5 M
dbacp00165 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.6% inhibition at 10-4 M
dbacp00166 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.2% inhibition at 10-3 M
dbacp00167 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.2% inhibition at 10-5 M
dbacp00168 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.3% inhibition at 10-4 M
dbacp00169 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 19.4% inhibition at 10-3 M
dbacp00170 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.6% inhibition at 10-6 M
dbacp00171 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.8% inhibition at 10-5 M
dbacp00172 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 12.4% inhibition at 10-4 M
dbacp00173 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 22.4% inhibition at 10-3 M
dbacp00174 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 17.0% inhibition at 10-6 M
dbacp00175 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.5% inhibition at 10-5 M
dbacp00176 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.5% inhibition at 10-4 M
dbacp00177 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 25.3% inhibition at 10-3 M
dbacp00178 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-6 M
dbacp00179 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.9% inhibition at 10-5 M
dbacp00180 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-4 M
dbacp00181 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.6% inhibition at 10-3 M
dbacp00182 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 15.6% inhibition at 10-3 M
dbacp00192 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 1.0% inhibition at 10-6 M
dbacp00193 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 10.1% inhibition at 10-5 M
dbacp00194 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 16.8% inhibition at 10-4 M
dbacp00195 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 36.1% inhibition at 10-3 M
dbacp00196 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 4.9% inhibition at 10-6 M
dbacp00197 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 10.2% inhibition at 10-5 M
dbacp00198 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 13.3% inhibition at 10-4 M
dbacp00199 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.0% inhibition at 10-3 M
dbacp00200 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 0.8% inhibition at 10-6 M
dbacp00201 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.4% inhibition at 10-5 M
dbacp00202 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.4% inhibition at 10-4 M
dbacp00203 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 18.3% inhibition at 10-3 M
dbacp00204 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.3% inhibition at 10-6 M
dbacp00205 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 11.0% inhibition at 10-5M
dbacp00206 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.9% inhibition at 10-4 M
dbacp00207 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 23.7% inhibition at 10-3 M
dbacp00208 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 12.2% inhibition at 10-6 M
dbacp00209 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 15.5% inhibition at 10-5 M
dbacp00210 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 24.7% inhibition at 10-4 M
dbacp00211 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 29.0% inhibition at 10-3 M
dbacp00212 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.0% inhibition at 10-6 M
dbacp00213 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.4% inhibition at 10-5 M
dbacp00214 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 18.5% inhibition at 10-4 M
dbacp00215 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 10.6% inhibition at 10-3 M
dbacp00216 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 22.8% inhibition at 10-3 M
dbacp00226 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 13.7% inhibition at 10-6 M
dbacp00227 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 25.8% inhibition at 10-5 M
dbacp00228 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 34.7% inhibition at 10-4 M
dbacp00229 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 44.5% inhibition at 10-3 M
dbacp00230 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 8.5% inhibition at 10-6 M
dbacp00231 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.5% inhibition at 10-5 M
dbacp00232 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 15.4% inhibition at 10-4 M
dbacp00233 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 24.1% inhibition at 10-3 M
dbacp00234 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.4% inhibition at 10-6 M
dbacp00235 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.5% inhibition at 10-5 M
dbacp00236 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 11.4% inhibition at 10-4 M
dbacp00237 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 23.2% inhibition at 10-3 M
dbacp00238 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 16.2% inhibition at 10-6 M
dbacp00239 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 6.6% inhibition at 10-5 M
dbacp00240 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.1% inhibition at 10-4 M
dbacp00241 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 14.5% inhibition at 10-3 M
dbacp00242 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 26.4% inhibition at 10-6 M
dbacp00243 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.1% inhibition at 10-5 M
dbacp00244 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 14.6% inhibition at 10-4 M
dbacp00245 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 38.4% inhibition at 10-3 M
dbacp00246 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 17.7% inhibition at 10-6 M
dbacp00247 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 10.9% inhibition at 10-5 M
dbacp00248 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 12.1% inhibition at 10-4 M
dbacp00249 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-3 M
dbacp00250 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 9.6% inhibition at 10-4 M
dbacp00251 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 29.9% inhibition at 10-3 M
dbacp00279 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 3.9% inhibition at 10-5 M
dbacp00280 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 45% inhibition at 10-3 M
dbacp00281 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.3% inhibition at 10-3 M
dbacp00282 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.1% inhibition at 10-6 M
dbacp00283 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 70.7% inhibition at 10-5 M
dbacp00284 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 34.4% inhibition at 10-3 M
dbacp00285 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.2% inhibition at 10-3 M
dbacp00286 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 11.08% inhibition at 10-5 M
dbacp00287 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 47.0% inhibition at 10-3 M
dbacp00288 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 2.2% inhibition at 10-6 M
dbacp00289 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.1% inhibition at 10-5 M
dbacp00290 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 6.9% inhibition at 10-4 M
dbacp00291 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 25.9% inhibition at 10-3 M
dbacp00312 (HHPHG)2 HHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 11.6 µM
dbacp00313 (HHPHG)2 HHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 26.9 µM
dbacp00314 (HHPHG)3 HHPHGHHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 1.25 µM
dbacp00315 (HHPHG)3 HHPHGHHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 1.56 µM
dbacp00316 (HHPHG)4 HHPHGHHPHGHHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 0.256 µM
dbacp00317 (HHPHG)4 HHPHGHHPHGHHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 0.245 µM
dbacp00318 (RGD-4C)-GG-D(KLAKLAK)2 ACDCRGDCFCGGKLAKLAKKLAKLAK Synthetic Peptide Apoptosis inducing Internalization assay,Mitochondrial swelling assay,Cell-free apoptosis assay,Caspase activation assay KS1767 Not specified LC50 : 10 μM
dbacp00322 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 46.2 ± 7.6 μM
dbacp00323 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 46.2 ± 7.6 μM
dbacp00324 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 46.2 ± 7.6 μM
dbacp00325 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 46.2 ± 7.6 μM
dbacp00326 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 46.2 ± 7.6 μM
dbacp00327 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 2.3 ± 0.2 μM
dbacp00328 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 2.3 ± 0.2 μM
dbacp00329 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 2.3 ± 0.2 μM
dbacp00330 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 2.3 ± 0.2 μM
dbacp00331 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 2.3 ± 0.2 μM
dbacp00332 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 30.8 ± 2.0 μM
dbacp00333 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 30.8 ± 2.0 μM
dbacp00334 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 30.8 ± 2.0 μM
dbacp00335 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 30.8 ± 2.0 μM
dbacp00336 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 30.8 ± 2.0 μM
dbacp00337 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : 36.2 ± 2.8 μM
dbacp00338 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : 36.2 ± 2.8 μM
dbacp00339 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : 36.2 ± 2.8 μM
dbacp00340 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : 36.2 ± 2.8 μM
dbacp00341 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 36.2 ± 2.8 μM
dbacp00342 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 29.0 ± 3.7 μM
dbacp00343 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 29.0 ± 3.7 μM
dbacp00344 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 29.0 ± 3.7 μM
dbacp00345 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 29.0 ± 3.7 μM
dbacp00346 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 29.0 ± 3.7 μM
dbacp00347 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 6.4 ± 0.6 μM
dbacp00348 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 6.4 ± 0.6 μM
dbacp00349 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 6.4 ± 0.6 μM
dbacp00350 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 6.4 ± 0.6 μM
dbacp00351 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 6.4 ± 0.6 μM
dbacp00352 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Epithelial cancer CC50 : 33.3 ±7.4 μM
dbacp00353 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Chronic myeloid Leukemia CC50 : 33.3 ±7.4 μM
dbacp00354 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Gastric cancer CC50 : 33.3 ±7.4 μM
dbacp00355 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Breast cancer CC50 : 33.3 ±7.4 μM
dbacp00356 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 33.3 ±7.4 μM
dbacp00357 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Epithelial cancer CC50 : 9.5 ± 0.5 μM
dbacp00358 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Chronic myeloid Leukemia CC50 : 9.5 ± 0.5 μM
dbacp00359 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Gastric cancer CC50 : 9.5 ± 0.5 μM
dbacp00360 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Breast cancer CC50 : 9.5 ± 0.5 μM
dbacp00361 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 9.5 ± 0.5 μM
dbacp00362 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 51.0 ± 4.6 μM
dbacp00363 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 51.0 ± 4.6 μM
dbacp00364 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 51.0 ± 4.6 μM
dbacp00365 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 51.0 ± 4.6 μM
dbacp00366 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 51.0 ± 4.6 μM
dbacp00367 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 4.6 ± 0.2 μM
dbacp00368 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 4.6 ± 0.2 μM
dbacp00369 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 4.6 ± 0.2 μM
dbacp00370 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 4.6 ± 0.2 μM
dbacp00371 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 4.6 ± 0.2 μM
dbacp00372 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 15.6 ± 3.6 μM
dbacp00373 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 15.6 ± 3.6 μM
dbacp00374 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 15.6 ± 3.6 μM
dbacp00375 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 15.6 ± 3.6 μM
dbacp00376 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 15.6 ± 3.6 μM
dbacp00377 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : > 64 μM
dbacp00378 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : > 64 μM
dbacp00379 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : > 64 μM
dbacp00380 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : > 64 μM
dbacp00381 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : > 64 μM
dbacp00382 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 37.5 ± 3.3 μM
dbacp00383 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 37.5 ± 3.3 μM
dbacp00384 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 37.5 ± 3.3 μM
dbacp00385 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 37.5 ± 3.3 μM
dbacp00386 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 37.5 ± 3.3 μM
dbacp00387 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 1.4 ± 0.2 μM
dbacp00388 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 1.4 ± 0.2 μM
dbacp00389 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 1.4 ± 0.2 μM
dbacp00390 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 1.4 ± 0.2 μM
dbacp00391 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 1.4 ± 0.2 μM
dbacp00392 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Epithelial cancer CC50 : 38.5 ± 4.8 μM
dbacp00393 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Chronic myeloid Leukemia CC50 : 38.5 ± 4.8 μM
dbacp00394 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Gastric cancer CC50 : 38.5 ± 4.8 μM
dbacp00395 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Breast cancer CC50 : 38.5 ± 4.8 μM
dbacp00396 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 38.5 ± 4.8 μM
dbacp00397 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Epithelial cancer CC50 : 15.5 ± 0.8 μM
dbacp00398 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Chronic myeloid Leukemia CC50 : 15.5 ± 0.8 μM
dbacp00399 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Gastric cancer CC50 : 15.5 ± 0.8 μM
dbacp00400 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Breast cancer CC50 : 15.5 ± 0.8 μM
dbacp00401 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 15.5 ± 0.8 μM
dbacp00403 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 22.5 ± 3.3 μM
dbacp00404 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 22.5 ± 3.3 μM
dbacp00405 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 22.5 ± 3.3 μM
dbacp00406 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 22.5 ± 3.3 μM
dbacp00407 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 22.5 ± 3.3 μM
dbacp00408 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 3.0 ± 0.1 μM
dbacp00409 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 3.0 ± 0.1 μM
dbacp00410 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 3.0 ± 0.1 μM
dbacp00411 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 3.0 ± 0.1 μM
dbacp00412 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 3.0 ± 0.1 μM
dbacp00413 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 14.9 ± 0.8 μM
dbacp00414 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 14.9 ± 0.8 μM
dbacp00415 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 14.9 ± 0.8 μM
dbacp00416 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 14.9 ± 0.8 μM
dbacp00417 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 14.9 ± 0.8 μM
dbacp00418 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : 51.5 ± 3.9 μM
dbacp00419 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : 51.5 ± 3.9 μM
dbacp00420 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : 51.5 ± 3.9 μM
dbacp00421 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : 51.5 ± 3.9 μM
dbacp00422 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 51.5 ± 3.9 μM
dbacp00423 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 3.9 ± 0.2 μM
dbacp00424 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 3.9 ± 0.2 μM
dbacp00425 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 3.9 ± 0.2 μM
dbacp00426 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 3.9 ± 0.2 μM
dbacp00427 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.9 ± 0.2 μM
dbacp00428 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Epithelial cancer CC50 : 14.1 ± 0.9 μM
dbacp00429 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Chronic myeloid Leukemia CC50 : 14.1 ± 0.9 μM
dbacp00430 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Gastric cancer CC50 : 14.1 ± 0.9 μM
dbacp00431 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Breast cancer CC50 : 14.1 ± 0.9 μM
dbacp00432 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 14.1 ± 0.9 μM
dbacp00440 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 19.5 ± 0.5 μM
dbacp00441 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 19.5 ± 0.5 μM
dbacp00442 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 19.5 ± 0.5 μM
dbacp00443 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 19.5 ± 0.5 μM
dbacp00444 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 19.5 ± 0.5 μM
dbacp00445 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 1.7 ± 0.1 μM
dbacp00446 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 1.7 ± 0.1 μM
dbacp00447 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 1.7 ± 0.1 μM
dbacp00448 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 1.7 ± 0.1 μM
dbacp00449 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 1.7 ± 0.1 μM
dbacp00450 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 9.0 ± 0.5 μM
dbacp00451 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 9.0 ± 0.5 μM
dbacp00452 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 9.0 ± 0.5 μM
dbacp00453 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 9.0 ± 0.5 μM
dbacp00454 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 9.0 ± 0.5 μM
dbacp00455 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : 44.2 ± 2.2 μM
dbacp00456 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : 44.2 ± 2.2 μM
dbacp00457 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : 44.2 ± 2.2 μM
dbacp00458 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : 44.2 ± 2.2 μM
dbacp00459 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 44.2 ± 2.2 μM
dbacp00460 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 6.7 ± 0.7 μM
dbacp00461 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 6.7 ± 0.7 μM
dbacp00462 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 6.7 ± 0.7 μM
dbacp00463 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 6.7 ± 0.7 μM
dbacp00464 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 6.7 ± 0.7 μM
dbacp00465 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 2.1 ± 0.2 μM
dbacp00466 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 2.1 ± 0.2 μM
dbacp00467 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 2.1 ± 0.2 μM
dbacp00468 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 2.1 ± 0.2 μM
dbacp00469 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 2.1 ± 0.2 μM
dbacp00470 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Epithelial cancer CC50 : 9.0 ± 1.1μM
dbacp00471 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Chronic myeloid Leukemia CC50 : 9.0 ± 1.1μM
dbacp00472 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Gastric cancer CC50 : 9.0 ± 1.1μM
dbacp00473 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Breast cancer CC50 : 9.0 ± 1.1μM
dbacp00474 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 9.0 ± 1.1μM
dbacp00475 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Epithelial cancer CC50 : 5.1 ± 0.3 μM
dbacp00476 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Chronic myeloid Leukemia CC50 : 5.1 ± 0.3 μM
dbacp00477 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Gastric cancer CC50 : 5.1 ± 0.3 μM
dbacp00478 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Breast cancer CC50 : 5.1 ± 0.3 μM
dbacp00479 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 5.1 ± 0.3 μM
dbacp00480 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 26.5 ± 2.4 μM
dbacp00481 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 26.5 ± 2.4 μM
dbacp00482 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 26.5 ± 2.4 μM
dbacp00483 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 26.5 ± 2.4 μM
dbacp00484 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 26.5 ± 2.4 μM
dbacp00485 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 2.0 ± 0.1 μM
dbacp00486 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 2.0 ± 0.1 μM
dbacp00487 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 2.0 ± 0.1 μM
dbacp00488 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 2.0 ± 0.1 μM
dbacp00489 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 2.0 ± 0.1 μM
dbacp00490 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 14.7 ± 1.5 μM
dbacp00491 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 14.7 ± 1.5 μM
dbacp00492 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 14.7 ± 1.5 μM
dbacp00493 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 14.7 ± 1.5 μM
dbacp00494 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 14.7 ± 1.5 μM
dbacp00495 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : 20.9 ± 1.4 μM
dbacp00496 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : 20.9 ± 1.4 μM
dbacp00497 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : 20.9 ± 1.4 μM
dbacp00498 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : 20.9 ± 1.4 μM
dbacp00499 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 20.9 ± 1.4 μM
dbacp00500 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 15.2 ± 1.9 μM
dbacp00501 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 15.2 ± 1.9 μM
dbacp00502 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 15.2 ± 1.9 μM
dbacp00503 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 15.2 ± 1.9 μM
dbacp00504 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.2 ± 1.9 μM
dbacp00505 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 1.3 ± 0.1 μM
dbacp00506 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 1.3 ± 0.1 μM
dbacp00507 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 1.3 ± 0.1 μM
dbacp00508 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 1.3 ± 0.1 μM
dbacp00509 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 1.3 ± 0.1 μM
dbacp00510 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Epithelial cancer CC50 : 15.7 ±1.1μM
dbacp00511 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Chronic myeloid Leukemia CC50 : 15.7 ±1.1μM
dbacp00512 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Gastric cancer CC50 : 15.7 ±1.1μM
dbacp00513 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Breast cancer CC50 : 15.7 ±1.1μM
dbacp00514 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 15.7 ±1.1μM
dbacp00515 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Epithelial cancer CC50 : 10.4 ± 1.0 μM
dbacp00516 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Chronic myeloid Leukemia CC50 : 10.4 ± 1.0 μM
dbacp00517 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Gastric cancer CC50 : 10.4 ± 1.0 μM
dbacp00518 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Breast cancer CC50 : 10.4 ± 1.0 μM
dbacp00519 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 10.4 ± 1.0 μM
dbacp00520 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 29.4 ± 1.1 μM
dbacp00521 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 29.4 ± 1.1 μM
dbacp00522 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 29.4 ± 1.1 μM
dbacp00523 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 29.4 ± 1.1 μM
dbacp00524 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 29.4 ± 1.1 μM
dbacp00525 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 5.0 ± 0.3 μM
dbacp00526 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 5.0 ± 0.3 μM
dbacp00527 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 5.0 ± 0.3 μM
dbacp00528 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 5.0 ± 0.3 μM
dbacp00529 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 5.0 ± 0.3 μM
dbacp00530 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 34.5 ± 3.6 μM
dbacp00531 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 34.5 ± 3.6 μM
dbacp00532 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 34.5 ± 3.6 μM
dbacp00533 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 34.5 ± 3.6 μM
dbacp00534 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 34.5 ± 3.6 μM
dbacp00535 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : 39.4 ± 2.6 μM
dbacp00536 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : 39.4 ± 2.6 μM
dbacp00537 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : 39.4 ± 2.6 μM
dbacp00538 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : 39.4 ± 2.6 μM
dbacp00539 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 39.4 ± 2.6 μM
dbacp00540 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 3.1 ± 0.1 μM
dbacp00541 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 3.1 ± 0.1 μM
dbacp00542 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 3.1 ± 0.1 μM
dbacp00543 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 3.1 ± 0.1 μM
dbacp00544 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.1 ± 0.1 μM
dbacp00545 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 18.3 ± 1.4 μM
dbacp00546 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 18.3 ± 1.4 μM
dbacp00547 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 18.3 ± 1.4 μM
dbacp00548 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 18.3 ± 1.4 μM
dbacp00549 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 18.3 ± 1.4 μM
dbacp00550 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 4.0 ± 0.1 μM
dbacp00551 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 4.0 ± 0.1 μM
dbacp00552 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 4.0 ± 0.1 μM
dbacp00553 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 4.0 ± 0.1 μM
dbacp00554 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 4.0 ± 0.1 μM
dbacp00555 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 25.0 ± 2.9 μM
dbacp00556 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 25.0 ± 2.9 μM
dbacp00557 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 25.0 ± 2.9 μM
dbacp00558 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 25.0 ± 2.9 μM
dbacp00559 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 25.0 ± 2.9 μM
dbacp00560 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : 17.1 ± 0.7 μM
dbacp00561 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : 17.1 ± 0.7 μM
dbacp00562 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : 17.1 ± 0.7 μM
dbacp00563 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : 17.1 ± 0.7 μM
dbacp00564 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 17.1 ± 0.7 μM
dbacp00565 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 1.0 ± 0.1 μM
dbacp00566 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 1.0 ± 0.1 μM
dbacp00567 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 1.0 ± 0.1 μM
dbacp00568 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 1.0 ± 0.1 μM
dbacp00569 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 1.0 ± 0.1 μM
dbacp00573 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : > 64 μM
dbacp00574 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : > 64 μM
dbacp00575 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : > 64 μM
dbacp00576 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : > 64 μM
dbacp00577 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : > 64 μM
dbacp00578 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 10.3 ± 1.1 μM
dbacp00579 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 10.3 ± 1.1 μM
dbacp00580 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 10.3 ± 1.1 μM
dbacp00581 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 10.3 ± 1.1 μM
dbacp00582 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 10.3 ± 1.1 μM
dbacp00583 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 51.2 ± 4.0 μM
dbacp00584 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 51.2 ± 4.0 μM
dbacp00585 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 51.2 ± 4.0 μM
dbacp00586 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 51.2 ± 4.0 μM
dbacp00587 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 51.2 ± 4.0 μM
dbacp00588 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : > 64 μM
dbacp00589 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : > 64 μM
dbacp00590 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : > 64 μM
dbacp00591 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : > 64 μM
dbacp00592 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : > 64 μM
dbacp00593 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 48.4 ± 0.7 μM
dbacp00594 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 48.4 ± 0.7 μM
dbacp00595 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 48.4 ± 0.7 μM
dbacp00596 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 48.4 ± 0.7 μM
dbacp00597 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 48.4 ± 0.7 μM
dbacp00598 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 11.5 ± 0.6 μM
dbacp00599 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 11.5 ± 0.6 μM
dbacp00600 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 11.5 ± 0.6 μM
dbacp00601 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 11.5 ± 0.6 μM
dbacp00602 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 11.5 ± 0.6 μM
dbacp00603 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Epithelial cancer CC50 : 34.1 ± 3.9 μM
dbacp00604 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Chronic myeloid Leukemia CC50 : 34.1 ± 3.9 μM
dbacp00605 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Gastric cancer CC50 : 34.1 ± 3.9 μM
dbacp00606 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Breast cancer CC50 : 34.1 ± 3.9 μM
dbacp00607 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 34.1 ± 3.9 μM
dbacp00608 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Epithelial cancer CC50 : 30.8 ± 2.5 μM
dbacp00609 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Chronic myeloid Leukemia CC50 : 30.8 ± 2.5 μM
dbacp00610 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Gastric cancer CC50 : 30.8 ± 2.5 μM
dbacp00611 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Breast cancer CC50 : 30.8 ± 2.5 μM
dbacp00612 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 30.8 ± 2.5 μM
dbacp00621 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 30.3 ± 1.1 μM
dbacp00622 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 30.3 ± 1.1 μM
dbacp00623 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 30.3 ± 1.1 μM
dbacp00624 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 30.3 ± 1.1 μM
dbacp00625 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 30.3 ± 1.1 μM
dbacp00626 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 4.0 ± 0.1 μM
dbacp00627 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 4.0 ± 0.1 μM
dbacp00628 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 4.0 ± 0.1 μM
dbacp00629 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 4.0 ± 0.1 μM
dbacp00630 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 4.0 ± 0.1 μM
dbacp00631 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 68.4 ± 9.6 μM
dbacp00632 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 68.4 ± 9.6 μM
dbacp00633 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 68.4 ± 9.6 μM
dbacp00634 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 68.4 ± 9.6 μM
dbacp00635 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 68.4 ± 9.6 μM
dbacp00636 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : 50.4 ± 2.4 μM
dbacp00637 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : 50.4 ± 2.4 μM
dbacp00638 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : 50.4 ± 2.4 μM
dbacp00639 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : 50.4 ± 2.4 μM
dbacp00640 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 50.4 ± 2.4 μM
dbacp00641 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 2.7 ± 0.1 μM
dbacp00642 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 2.7 ± 0.1 μM
dbacp00643 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 2.7 ± 0.1 μM
dbacp00644 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 2.7 ± 0.1 μM
dbacp00645 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 2.7 ± 0.1 μM
dbacp00646 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 31.6 ± 1.3 μM
dbacp00647 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 31.6 ± 1.3 μM
dbacp00648 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 31.6 ± 1.3 μM
dbacp00649 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 31.6 ± 1.3 μM
dbacp00650 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 31.6 ± 1.3 μM
dbacp00651 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 5.4 ± 0.3 μM
dbacp00652 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 5.4 ± 0.3 μM
dbacp00653 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 5.4 ± 0.3 μM
dbacp00654 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 5.4 ± 0.3 μM
dbacp00655 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 5.4 ± 0.3 μM
dbacp00656 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 31.3 ± 2.6 μM
dbacp00657 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 31.3 ± 2.6 μM
dbacp00658 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 31.3 ± 2.6 μM
dbacp00659 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 31.3 ± 2.6 μM
dbacp00660 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 31.3 ± 2.6 μM
dbacp00661 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : 41.0 ± 4.2 μM
dbacp00662 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : 41.0 ± 4.2 μM
dbacp00663 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : 41.0 ± 4.2 μM
dbacp00664 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : 41.0 ± 4.2 μM
dbacp00665 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 41.0 ± 4.2 μM
dbacp00666 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 15.1 ± 1.4 μM
dbacp00667 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 15.1 ± 1.4 μM
dbacp00668 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 15.1 ± 1.4 μM
dbacp00669 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 15.1 ± 1.4 μM
dbacp00670 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.1 ± 1.4 μM
dbacp00671 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 3.9 ± 0.1 μM
dbacp00672 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 3.9 ± 0.1 μM
dbacp00673 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 3.9 ± 0.1 μM
dbacp00674 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 3.9 ± 0.1 μM
dbacp00675 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.9 ± 0.1 μM
dbacp00676 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 23.3 ± 0.4 μM
dbacp00677 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid Leukemia CC50 : 23.3 ± 0.4 μM
dbacp00678 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 23.3 ± 0.4 μM
dbacp00679 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 23.3 ± 0.4 μM
dbacp00680 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 23.3 ± 0.4 μM
dbacp00681 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 5.1 ± 0.3 μM
dbacp00682 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid Leukemia CC50 : 5.1 ± 0.3 μM
dbacp00683 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 5.1 ± 0.3 μM
dbacp00684 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 5.1 ± 0.3 μM
dbacp00685 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 5.1 ± 0.3 μM
dbacp00686 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 39.7 ± 3.8 μM
dbacp00687 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid Leukemia CC50 : 39.7 ± 3.8 μM
dbacp00688 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 39.7 ± 3.8 μM
dbacp00689 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 39.7 ± 3.8 μM
dbacp00690 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 39.7 ± 3.8 μM
dbacp00691 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : > 64 μM
dbacp00692 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid Leukemia CC50 : > 64 μM
dbacp00693 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : > 64 μM
dbacp00694 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : > 64 μM
dbacp00695 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : > 64 μM
dbacp00696 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 3.9 ± 0.2 μM
dbacp00697 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid Leukemia CC50 : 3.9 ± 0.2 μM
dbacp00698 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 3.9 ± 0.2 μM
dbacp00699 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 3.9 ± 0.2 μM
dbacp00700 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.9 ± 0.2 μM
dbacp00704 10a NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 28 µM
dbacp00705 10b NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 11.4 µM
dbacp00706 10c NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 6.6 µM
dbacp00707 11a NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 5.2 µM
dbacp00708 11b NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 19 µM
dbacp00709 11c NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 7.2 µM
dbacp00710 12a NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 6.1 µM
dbacp00711 12b NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 27 µM
dbacp00712 12c NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 14 µM
dbacp00805 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test C4-2B Prostate cancer IC50 : 29.05 μM
dbacp00806 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test C4-2B Lung cancer IC50 : 29.05 μM
dbacp00807 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test A549 Prostate cancer IC50 : 14.97 μM
dbacp00808 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test A549 Lung cancer IC50 : 14.97 μM
dbacp00809 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test U87 Prostate cancer IC50 : 14.8 μM
dbacp00810 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test U87 Lung cancer IC50 : 14.8 μM
dbacp00811 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test MCF-7 Prostate cancer IC50 : 14.16 μM
dbacp00812 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test MCF-7 Lung cancer IC50 : 14.16 μM
dbacp00951 ABP-dHC-Cecropin A RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK Synthetic construct Apoptosis inducing MTT assay K562 cells Leukemia IC50 : 349.5 μM
dbacp00952 ABP-dHC-Cecropin A RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK Synthetic construct Apoptosis inducing MTT assay U937 cells Leukemia IC50 : 303.2 μM
dbacp00953 ABP-dHC-Cecropin A RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK Synthetic construct Apoptosis inducing MTT assay THP-1 cells Leukemia IC50 : 228.5 μM
dbacp00954 ABP-dHC-Cecropin A-K RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK Synthetic construct Apoptosis inducing MTT assay K562 cells Leukemia IC50 : 349.5 μM
dbacp00955 ABP-dHC-Cecropin A-K RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK Synthetic construct Apoptosis inducing MTT assay U937 cells Leukemia IC50 : 303.2 μM
dbacp00956 ABP-dHC-Cecropin A-K RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK Synthetic construct Apoptosis inducing MTT assay THP-1 cells Leukemia IC50 : 228.5 μM
dbacp01174 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 50% inhibition at 2.5 µg/ml
dbacp01175 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 40% inhibition at 5 µg/ml
dbacp01176 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 75% inhibition at 10 µg/ml
dbacp01177 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 40% inhibition at 2.5 µg/ml
dbacp01178 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 42% inhibition at 5 µg/ml
dbacp01179 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 52% inhibition at 10 µg/ml
dbacp01186 APQQ NA Synthetic construct Cell metatstasis inhibition Transwell assay MDA-MB-231 Breast cancer Not found
dbacp01187 APQQ NA Synthetic construct Cell metatstasis inhibition Transwell assay MCF-7 Breast cancer Not found
dbacp01188 APQQ NA Synthetic construct Cell metatstasis inhibition Transwell assay U251 Brain cancer Not found
dbacp01192 Ascaphin-8 [T16A] GFKDLLKGAAKALVKAVLF Synthetic construct Not specified Not specified Not found Liver cancer Not found
dbacp01442 Baceridin cyclo(L-Trp-D-Ala-D-allo-Ile-L-Val-D-Leu-L-Leu-) Synthetic construct Apoptosis inducing MTT assay HCT116 Not specified Not found
dbacp01443 Baceridin cyclo(L-Trp-D-Ala-D-allo-Ile-L-Val-D-Leu-L-Leu-) Synthetic construct Apoptosis inducing MTT assay RKO Not specified Not found
dbacp01444 Baceridin cyclo(L-Trp-D-Ala-D-allo-Ile-L-Val-D-Leu-L-Leu-) Synthetic construct Apoptosis inducing MTT assay HeLa Not specified Not found
dbacp01598 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90-100% viablity
dbacp01599 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 10 µM 90-95% viablity
dbacp01600 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 100 µM 90-100% viablity
dbacp01892 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 32.5 ± 0.5 μM
dbacp01893 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 29.5 ± 2 μM
dbacp01894 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 46.0 ± 3 μM
dbacp01895 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 50.0 ± 10 μM
dbacp01896 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 40.0 ± 3 Μm
dbacp01897 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 31.2 ± 5 μM
dbacp01898 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 22.5 ± 0 μM
dbacp01899 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 32.5 ± 4 μM
dbacp01900 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 28.0 ± 3 μM
dbacp01901 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 32.5 ± 11 μM
dbacp01902 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 40.0 ± 7 μM
dbacp01903 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 24.5 ± 0.7 μM
dbacp01904 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 34.5 ± 2 μM
dbacp01905 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 35.0 ± 7 μM
dbacp01906 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 51.0 ± 6 Μm
dbacp01907 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 40.7 ± 3 μM
dbacp01908 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 38.5 ± 4 μM
dbacp01909 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 44.0 ± 3 μM
dbacp01910 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 47.5 ± 4 μM
dbacp01911 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 44.5 ± 0.7 Μm
dbacp02108 cMastoparan-C(cMP-C) CLNLKALLAVAKKILC Synthetic construct Apoptosis MTT assay H157 Non-small cell Lung cancer IC50 : 7.02 μM
dbacp02109 cMastoparan-C(cMP-C) CLNLKALLAVAKKILC Synthetic construct Apoptosis MTT assay MBD-MB-435S Melanocyte IC50 : 13.87 μM
dbacp02110 cMastoparan-C(cMP-C) CLNLKALLAVAKKILC Synthetic construct Apoptosis MTT assay PC-3 Human prostate carcinoma IC50 : 13.87 μM
dbacp02111 cMastoparan-C(cMP-C) CLNLKALLAVAKKILC Synthetic construct Apoptosis MTT assay U251-MG Human glioblastoma astrocytoma IC50 : 8.56 μM
dbacp02112 cMastoparan-C(cMP-C) CLNLKALLAVAKKILC Synthetic construct Apoptosis MTT assay MCF-7 Human breast cancer IC50 : 13.66 μM
dbacp02145 C1 KKWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 10 ±2 µMol/L
dbacp02146 C1 KKWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 22 ±5 µMol/L
dbacp02148 C2 KWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 7.9 ± 0.3 µMol/L
dbacp02149 C2 KWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 1.71 ± 0.6 µMol/L
dbacp02150 C3 KKβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 15 ± 2 µMol/L
dbacp02151 C3 KKβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 92 ± 2 µMol/L
dbacp02152 C4 KWβ2,2KK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 12.6 ± 0.6 µMol/L
dbacp02153 C4 KWβ2,2KK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 99 ± 15 µMol/L
dbacp02154 C5 KKWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 11 ± 2 µMol/L
dbacp02155 C5 KKWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 23 ± 3 µMol/L
dbacp02156 C6 KWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 8 ± 1 µMol/L
dbacp02157 C6 KWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 26 ± 2 µMol/L
dbacp02158 C7 KKβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 16 ± 5 µMol/L
dbacp02159 C7 KKβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 157 ± 30 µMol/L
dbacp02160 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :10.6 ± 0.4 µM
dbacp02161 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :13.0 ± 1.0 µM
dbacp02162 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :12.1 ± 1.6 µM
dbacp02163 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :37 ± 4.3 µM
dbacp02181 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.4 ± 0.2 µM
dbacp02182 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 2.0 µM
dbacp02183 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.3 ± 0.5 µM
dbacp02184 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 1.0 µM
dbacp02206 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.8 ± 2.0 µM
dbacp02207 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 9.3 ± 1.5 µM
dbacp02208 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.1 ± 0.9 µM
dbacp02222 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 7.5 ± 0.4 µM
dbacp02274 CAMP1 HVLFFFFNH2 Synthetic Cell membrane penetrating MTT assay UM-UC-5 Not specified IC50 : >100 μM
dbacp02275 CAMP1 HVLFFFFNH2 Synthetic Cell membrane penetrating MTT assay A549 Not specified IC50 : 12.39 μM
dbacp02276 CAMP2 HVLLFFFFNH2 Synthetic Cell membrane penetrating MTT assay UM-UC-5 Not specified IC50 : 21.61 μM
dbacp02277 CAMP2 HVLLFFFFNH2 Synthetic Cell membrane penetrating MTT assay A549 Not specified IC50 : 5.77μM
dbacp02278 CAMP3 HVLFFFFLFFNH2 Synthetic Cell membrane penetrating MTT assay UM-UC-5 Not specified IC50 : >100 μM
dbacp02279 CAMP3 HVLFFFFLFFNH2 Synthetic Cell membrane penetrating MTT assay A549 Not specified IC50 : 17.63μM
dbacp02280 CAMP5 HVLLLLLLLFNH2 Synthetic Cell membrane penetrating MTT assay UM-UC-5 Not specified IC50 : >100 μM
dbacp02281 CAMP5 HVLLLLLLLFNH2 Synthetic Cell membrane penetrating MTT assay A549 Not specified IC50 : 19.65 μM
dbacp02282 CAMP7 HVLLLLFFFFNH2 Synthetic Cell membrane penetrating MTT assay UM-UC-5 Not specified IC50 : >100 μM
dbacp02283 CAMP7 HVLLLLFFFFNH2 Synthetic Cell membrane penetrating MTT assay A549 Not specified IC50 : >100 μM
dbacp02321 CB KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Synthetic Cell membrane disintegration Not specified Ags Gastric cancer Not found
dbacp02395 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Epithelial cancer CC50 : 39.8 ± 1.0 μM
dbacp02396 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Chronic myeloid leukemia CC50 : 39.8 ± 1.0 μM
dbacp02397 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Gastric cancer CC50 : 39.8 ± 1.0 μM
dbacp02398 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Breast cancer CC50 : 39.8 ± 1.0 μM
dbacp02399 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 39.8 ± 1.0 μM
dbacp02400 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Epithelial cancer CC50 : 2.9 ± 0.1 μM
dbacp02401 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Chronic myeloid leukemia CC50 : 2.9 ± 0.1 μM
dbacp02402 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Gastric cancer CC50 : 2.9 ± 0.1 μM
dbacp02403 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Breast cancer CC50 : 2.9 ± 0.1 μM
dbacp02404 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 2.9 ± 0.1 μM
dbacp02405 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Epithelial cancer CC50 : 71.7 ± 9.2 μM
dbacp02406 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Chronic myeloid leukemia CC50 : 71.7 ± 9.2 μM
dbacp02407 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Gastric cancer CC50 : 71.7 ± 9.2 μM
dbacp02408 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Breast cancer CC50 : 71.7 ± 9.2 μM
dbacp02409 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 71.7 ± 9.2 μM
dbacp02410 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Epithelial cancer CC50 : > 64 μM
dbacp02411 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Chronic myeloid leukemia CC50 : > 64 μM
dbacp02412 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Gastric cancer CC50 : > 64 μM
dbacp02413 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Breast cancer CC50 : > 64 μM
dbacp02414 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : > 64 μM
dbacp02415 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 15.3 ± 1.4 μM
dbacp02416 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid leukemia CC50 : 15.3 ± 1.4 μM
dbacp02417 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 15.3 ± 1.4 μM
dbacp02418 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 15.3 ± 1.4 μM
dbacp02419 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.3 ± 1.4 μM
dbacp02420 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Epithelial cancer CC50 : 2.7 ± 0.1 μM
dbacp02421 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Chronic myeloid leukemia CC50 : 2.7 ± 0.1 μM
dbacp02422 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Gastric cancer CC50 : 2.7 ± 0.1 μM
dbacp02423 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Breast cancer CC50 : 2.7 ± 0.1 μM
dbacp02424 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 2.7 ± 0.1 μM
dbacp02425 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Epithelial cancer CC50 : 12.7 ± 1.1 μM
dbacp02426 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Chronic myeloid leukemia CC50 : 12.7 ± 1.1 μM
dbacp02427 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Gastric cancer CC50 : 12.7 ± 1.1 μM
dbacp02428 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Breast cancer CC50 : 12.7 ± 1.1 μM
dbacp02429 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 12.7 ± 1.1 μM
dbacp02556 CPP2 HVRRRRRRRNH2 Synthetic Cell membrane penetrating MTT assay UM-UC-A Not specified IC50 : 5.47 μM
dbacp02557 CPP2 HVRRRRRRRNH2 Synthetic Cell membrane penetrating MTT assay A549 Not specified IC50 : >100 μM
dbacp02558 CPP4 HVRRRRRRRRNH2 Synthetic Cell membrane penetrating MTT assay UM-UC-5 Not specified IC50 : >100 μM
dbacp02559 CPP4 HVRRRRRRRRNH2 Synthetic Cell membrane penetrating MTT assay A549 Not specified IC50 : >100 μM
dbacp02564 CRAMP-18 E2K GKKLKKIGQKIKNFFQKL Synthetic Disrupt cell membrane structure MTT assay K-562 Chronic myelogenous Leukemia IC50 : 20–34 uM
dbacp02565 CRAMP-18 E2K GKKLKKIGQKIKNFFQKL Synthetic Disrupt cell membrane structure MTT assay Jurkat Acute T cell Leukemia IC50 : 20–34 uM
dbacp02566 CRAMP-18 E2K GKKLKKIGQKIKNFFQKL Synthetic Disrupt cell membrane structure MTT assay K-549 Acute T cell Leukemia IC50 : 20–34 uM
dbacp02627 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer IC50 : 3.2 ± 0.6 µM
dbacp02628 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay KB Oral cancer IC50 : 4.5 ± 0.5 µM
dbacp02629 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : 4.7 ± 0.4 µM
dbacp02630 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : 3.2 ± 0.4 µM
dbacp02744 Dex-(KW)3 KWKWKW Synthetic Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer At 10 µM 60% viablity
dbacp02745 Dex-(KW)3 KWKWKW Synthetic Cell membrane disruption MTT/MTS assay MCF-7 Breast cancer At 10 µM 35-40% viablity
dbacp02757 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 1.31 nM
dbacp02758 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 2.85 nM
dbacp02759 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 0.62 nM
dbacp02826 EGFR-lytic YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK Synthetic Peptide Cell membrane lysis ELISA MDA-MB-231 Breast cancer IC50 : 0.12 µM
dbacp02827 EGFR-lytic YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK Synthetic Peptide Cell membrane lysis ELISA MDA-MB-231 Breast cancer IC50 : 0.46 µM
dbacp02914 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 2.5µg/ml
dbacp02915 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 5µg/ml
dbacp02916 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 10µg/ml
dbacp03067 GLK-19 GLKKLLGKLLKKLGKLLLK Synthetic construct Not specified Not specified Not found Not found Not found
dbacp03177 H-11 IKLSPETKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay A549 Not found IC50 : 1.82 ± 0.23 μM
dbacp03178 H-11 IKLSPETKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay HCT116 Not found IC50 : 6.50 ± 0.32 μM
dbacp03179 H-11 IKLSPETKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay HepG2 Not found IC50 : 4.96 ± 0.43 μM
dbacp03180 H-12 IKLSKETKDNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay A549 Not found IC50 : 2.35 ± 0.31 μM
dbacp03181 H-12 IKLSKETKDNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay HCT116 Not found IC50 : 8.09 ± 0.40 μM
dbacp03182 H-12 IKLSKETKDNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay HepG2 Not found IC50 : 4.28 ± 0.38 μM
dbacp03183 H-13 IKLSKETKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay A549 Not found IC50 : 1.17 ± 0.23 μM
dbacp03184 H-13 IKLSKETKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay HCT116 Not found IC50 : 4.93 ± 0.51 μM
dbacp03185 H-13 IKLSKETKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay HepG2 Not found IC50 : 2.46 ± 0.32 μM
dbacp03186 H-14 IKLSKKTKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay A549 Not found IC50 : 0.98 ± 0.11 μM
dbacp03187 H-14 IKLSKKTKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay HCT116 Not found IC50 : 1.841 ± 0.34 μM
dbacp03188 H-14 IKLSKKTKKNLKKVLKGAIKGAIAVAKMV Synthetic construct Inducing apoptosis MTT assay HepG2 Not found IC50 : 4.54 ± 0.25 μM
dbacp03289 HCAP18(109-135) FRKSKEKIGKEFKRIVQRIKDFLRNLV HCAP18 synthetic peptide Apoptosis inducing Not specified SAS-H1 Oral cancer Not found
dbacp03297 HHPHG HHPHG Synthetic Peptide Anti-angiogenesis Tropomyosin binding assay Not found Tumor IC50 : 92 µM
dbacp03530 KW5 KAAKKAAKAAKKAAKAAKKAA Synthetic peptide Through interactions with the plasma membrane MTT/MTS assay HT-29 Colon cancer IC50 : 55 ± 14 µM
dbacp04130 LK1 (Temporin-1CEa Analog peptide) FVDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 20.97 µM
dbacp04131 LK1 (Temporin-1CEa Analog peptide) FVDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay Bcap-37 Breast cancer IC50 : 18.7 µM
dbacp04132 LK1 (Temporin-1CEa Analog peptide) FVDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 66.4µM
dbacp04133 LK2(5) (Temporin-1CEa Analog peptide) FKDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 44.7 µM
dbacp04134 LK2(5) (Temporin-1CEa Analog peptide) FKDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay Bcap-37 Breast cancer IC50 : 83.49 µM
dbacp04135 LK2(5) (Temporin-1CEa Analog peptide) FKDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 894.7 µM
dbacp04136 LK2(6) (Temporin-1CEa Analog peptide) FVKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 15.54 µM
dbacp04137 LK2(6) (Temporin-1CEa Analog peptide) FVKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay Bcap-37 Breast cancer IC50 : 18.9 µM
dbacp04138 LK2(6) (Temporin-1CEa Analog peptide) FVKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 85.41 µM
dbacp04139 LK2(6)A(L) (Temporin-1CEa Analog peptide) FVKLKKILNIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 9.01 µM
dbacp04140 LK2(6)A(L) (Temporin-1CEa Analog peptide) FVKLKKILNIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay Bcap-37 Breast cancer IC50 : 10.52 µM
dbacp04141 LK2(6)A(L) (Temporin-1CEa Analog peptide) FVKLKKILNIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 34.74 µM
dbacp04142 LK2(6)AN(2L) (Temporin-1CEa Analog peptide) FVKLKKILNIILSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 11 µM
dbacp04143 LK2(6)AN(2L) (Temporin-1CEa Analog peptide) FVKLKKILNIILSIFKK Synthetic construct Cell membrane disintegration MTT-assay Bcap-37 Breast cancer IC50 : 9.39 µM
dbacp04144 LK2(6)AN(2L) (Temporin-1CEa Analog peptide) FVKLKKILNIILSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 41.55 µM
dbacp04145 LK3 (Temporin-1CEa Analog peptide) FKKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 27.72 µM
dbacp04146 LK3 (Temporin-1CEa Analog peptide) FKKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay Bcap-37 Breast cancer IC50 : 25.04 µM
dbacp04147 LK3 (Temporin-1CEa Analog peptide) FKKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 224.8 µM
dbacp04296 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 75 ± 5 µM
dbacp04297 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 73 ± 2 µM
dbacp04298 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 28 ± 0 µM
dbacp04299 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 38 ± 3 µM
dbacp04300 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 31 ± 3 µM
dbacp04301 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 14 ± 1 µM
dbacp04302 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay B16F1 Skin cancer IC50 : 13.3 µM
dbacp04303 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay A375 Skin cancer IC50 : 12.7 µM
dbacp04304 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : 15.3 µM
dbacp04305 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 248 ± 5 µM
dbacp04306 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 216 ± 36 µM
dbacp04307 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 78 ± 7 µM
dbacp04308 LTX-328 KAQ-Dip-QKQAW Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : >350 µM
dbacp04643 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :3.2 ± 0.1 µM
dbacp04644 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :2.1 ± 0.1 µM
dbacp04645 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :1.8 ± 0.1 µM
dbacp04646 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :1.4 ± 0.1 µM
dbacp04677 MG2d GIGKFLHSAKKWGKAFVGQIMNC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90-100% viablity
dbacp04794 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer > 100% cell viability at 5 µM
dbacp04795 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 60% cell viability at 50 µM
dbacp04796 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer 100% cell viability at 5 µM
dbacp04797 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer < 60% cell viability at 50 µM
dbacp04798 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 100% cell viability at 5 µM
dbacp04799 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 40% cell viability at 50 µM
dbacp04800 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer > 100% cell viability at 5 µM
dbacp04801 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 60% cell viability at 50 µM
dbacp04802 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer 100% cell viability at 5 µM
dbacp04803 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer < 60% cell viability at 50 µM
dbacp04804 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer 100% cell viability at 5 µM
dbacp04805 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 40% cell viability at 50 µM
dbacp04806 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 100% cell viability at 5 µM
dbacp04807 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 40% cell viability at 50 µM
dbacp04808 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer 100% cell viability at 5 µM
dbacp04809 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer < 40% cell viability at 50 µM
dbacp04810 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 100% cell viability at 5 µM
dbacp04811 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 20% cell viability at 50 µM
dbacp04812 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 100% cell viability at 5 µM
dbacp04813 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 40% cell viability at 50 µM
dbacp04814 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer 100% cell viability at 5 µM
dbacp04815 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer < 40% cell viability at 50 µM
dbacp04816 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 100% cell viability at 5 µM
dbacp04817 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 20% cell viability at 50 µM
dbacp04818 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer MIC : 5 µM
dbacp04855 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 70 µM
dbacp04856 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM
dbacp04857 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM
dbacp04858 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 40 µM
dbacp04872 NK-dpro (Derived from NK-2) KILPGVCKKIMRPFLRRISKDILTGKK Synthetic construct Not specified MTT assay EJ Not found IC50 : 28.7 μM
dbacp04873 NK-dpro (Derived from NK-2) KILPGVCKKIMRPFLRRISKDILTGKK Synthetic construct Not specified MTT assay PC-3 Not found IC50 : 9.6 μM
dbacp04874 NK-dpro (Derived from NK-2) KILPGVCKKIMRPFLRRISKDILTGKK Synthetic construct Not specified MTT assay T24 Not found IC50 : 39.6 μM
dbacp04875 NK-dpro (Derived from NK-2) KILPGVCKKIMRPFLRRISKDILTGKK Synthetic construct Not specified MTT assay HL-60 Not found IC50 : 48.4 μM
dbacp04876 NK-pro (Derived from NK-2) KILRGVCKKIMRPFLRRISKDILTGKK Synthetic construct Not specified MTT assay EJ Not found IC50 : 23.3 μM
dbacp04877 NK-pro (Derived from NK-2) KILRGVCKKIMRPFLRRISKDILTGKK Synthetic construct Not specified MTT assay PC-3 Not found IC50 : 9.3 μM
dbacp04878 NK-pro (Derived from NK-2) KILRGVCKKIMRPFLRRISKDILTGKK Synthetic construct Not specified MTT assay T24 Not found IC50 : 33.0 μM
dbacp04879 NK-pro (Derived from NK-2) KILRGVCKKIMRPFLRRISKDILTGKK Synthetic construct Not specified MTT assay HL-60 Not found IC50 : 26.1 μM
dbacp04880 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04881 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04882 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04883 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp05039 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 71.1 ± 2.84% cell viability at 20 µM
dbacp05040 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 50 ± 3.09% cell viability at 40 µM
dbacp05041 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 31.5 ± 1.49% cell viability at 60 µM
dbacp05042 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 13.8 ± 1.44% cell viability at 80 µM
dbacp05043 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 86 ± 0.57% cell viability at 10 µM
dbacp05044 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 63.8 ± 0.8% cell viability at 20 µM
dbacp05045 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 47.5 ± 1.66% cell viability at 40 µM
dbacp05046 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 26.9 ± 0.5% cell viability at 60 µM
dbacp05047 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 6.5 ± 1.07% cell viability at 80 µM
dbacp05051 P18 (Cecropin A(1-8)-Magainin 2(1ˆ’12) hybrid peptide Analogue) KWKLFKKIPKFLHLAKKF Synthetic construct Not specified Not specified Not found Not found Not found
dbacp05061 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 8% Inhibition at 10-10 M
dbacp05062 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 25% Inhibition at 10-9 M
dbacp05063 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 80% Inhibition at 10-8 M
dbacp05064 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 85% Inhibition at 10-7 M
dbacp05065 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 92% Inhibition at 10-6 M
dbacp05066 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 0.1% Inhibition at 10-10 M
dbacp05067 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 1% Inhibition at 10-9 M
dbacp05068 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 5% Inhibition at 10-8 M
dbacp05069 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 10% Inhibition at 10-7 M
dbacp05070 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 20% Inhibition at 10-6 M
dbacp05098 p776 GVGSPYVSRLLGICL Synthetic Peptide Inducing apoptosis ELISPOT assay Not found Tumor Not found
dbacp05102 p85 LIAHNQVRQV Synthetic Peptide Inducing apoptosis ELISPOT assay Not found Tumor Not found
dbacp05103 PA10 RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05104 PA10 RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay HCC1806 Breast cancer MIC : 10 μM
dbacp05105 PA10 RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay 184B5 Breast cancer MIC : 10 μM
dbacp05106 PA10 RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05107 PA15 RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05108 PA15 RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay HCC1806 Breast cancer MIC : 10 μM
dbacp05109 PA15 RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay 184B5 Breast cancer MIC : 10 μM
dbacp05110 PA15 RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05111 PA2 RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05112 PA2 RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay HCC1806 Breast cancer MIC : 10 μM
dbacp05113 PA2 RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay 184B5 Breast cancer MIC : 10 μM
dbacp05114 PA2 RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05115 PA3 RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05116 PA3 RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay HCC1806 Breast cancer MIC : 10 μM
dbacp05117 PA3 RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay 184B5 Breast cancer MIC : 10 μM
dbacp05118 PA3 RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05119 PA38 RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05120 PA38 RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay HCC1806 Breast cancer MIC : 10 μM
dbacp05121 PA38 RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay 184B5 Breast cancer MIC : 10 μM
dbacp05122 PA38 RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05123 PA49 RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05124 PA49 RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay HCC1806 Breast cancer MIC : 10 μM
dbacp05125 PA49 RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay 184B5 Breast cancer MIC : 10 μM
dbacp05126 PA49 RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05307 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 10.6 % inhibition of cell proliferation at 1 nM
dbacp05308 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 18.2 % inhibition of cell proliferation at 10 nM
dbacp05309 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 30.7 % inhibition of cell proliferation at 100 nM
dbacp05310 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 43.1 % inhibition of cell proliferation at 1 µM
dbacp05311 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 98.3 % inhibition of cell proliferation at 10 µM
dbacp05312 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 24.2 % inhibition of cell proliferation at 1 nM
dbacp05313 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 37.8 % inhibition of cell proliferation at 10 nM
dbacp05314 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 48.2 % inhibition of cell proliferation at 100 nM
dbacp05315 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 59.6 % inhibition of cell proliferation at 1 µM
dbacp05316 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 84.5 % inhibition of cell proliferation at 10 µM
dbacp05317 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 16.5 % inhibition of cell proliferation at 1 nM
dbacp05318 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 14.2 % inhibition of cell proliferation at 10 nM
dbacp05319 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 16.8 % inhibition of cell proliferation at 100 nM
dbacp05320 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 21.7 % inhibition of cell proliferation at 1 µM
dbacp05321 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 27.9 % inhibition of cell proliferation at 10 µM
dbacp05322 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 10.4 % inhibition of cell proliferation at 1 nM
dbacp05323 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 18.7 % inhibition of cell proliferation at 10 nM
dbacp05324 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 34.7 % inhibition of cell proliferation at 100 nM
dbacp05325 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 54.3 % inhibition of cell proliferation at 1 µM
dbacp05326 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 94.5 % inhibition of cell proliferation at 10 µM
dbacp05327 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer ED50 : 2.1 µM
dbacp05328 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer ED50 : 0.210 µM
dbacp05329 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer ED50 : >10 µM
dbacp05330 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer ED50 : 0.29 µM
dbacp05434 Peptide-1 IELLQARGGC-Pem Synthetic construct Cell membrane disintegration MTT/MTS assay HL-60 Leukemia cancer IC50 : 2.17 µM
dbacp05435 Peptide-1 IELLQARGGC-Pem Synthetic construct Cell membrane disintegration MTT/MTS assay NCI-H358 Lung cancer IC50 : 4.63 mM
dbacp05436 Peptide-2 IELLQARGGC-Pem-GGRRRRRRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HL-60 Leukemia cancer IC50 : 2.64 µM
dbacp05437 Peptide-2 IELLQARGGC-Pem-GGRRRRRRRR Synthetic construct Cell membrane disintegration MTT/MTS assay NCI-H358 Lung cancer IC50 : 2.19 µM
dbacp05438 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay HL-60 Leukemia cancer At 100 µM 90% viablity
dbacp05439 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay MDA-MB-231 Breast cancer At 100 µM 55% viablity
dbacp05440 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay HeLa Cervical cancer At 100 µM 50% viablity
dbacp05441 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay B16F10-Nex 2 Skin cancer At 100 µM 50% viablity
dbacp05442 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay A-2058 Skin cancer At100 µM 30% viablity
dbacp05443 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay Skmel-25 Skin cancer At 100 µM 55 - 60% viablity
dbacp05444 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay Skmel-28 Skin cancer At 100 µM 35 - 40% viablity
dbacp05445 Peptide-3 RRRRRRRRGGC-Pem Synthetic construct Cell membrane disintegration MTT/MTS assay HL-60 Leukemia cancer IC50 : 6.24 µM
dbacp05446 Peptide-3 RRRRRRRRGGC-Pem Synthetic construct Cell membrane disintegration MTT/MTS assay NCI-H358 Lung cancer IC50 : 8.41 µM
dbacp05706 PTP-7a FLGALFHALSKLL Synthetic peptide Inducing cell membrane damage MTT/MTS assay A-549 Lung cancer IC50 : 28 µM
dbacp05707 PTP-7b FLGALFKALSHLL Synthetic peptide Inducing cell membrane damage MTT/MTS assay A-549 Lung cancer IC50 : 32 µM
dbacp05825 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 0% apoptosis at 10 µM
dbacp05826 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 10% apoptosis at 20 µM
dbacp05827 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 30% apoptosis at 50 µM
dbacp05828 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 30% apoptosis at 10 µM
dbacp05829 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 80% apoptosis at 20 µM
dbacp05830 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 80% apoptosis at 50 µM
dbacp05831 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 20% apoptosis at 10 µM
dbacp05832 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor > 50% apoptosis at 20 µM
dbacp05833 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 30% apoptosis at 50 µM
dbacp05834 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 15% apoptosis at 10 µM
dbacp05835 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 20% apoptosis at 20 µM
dbacp05836 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 50% apoptosis at 50 µM
dbacp05839 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 8% apoptosis at 10 µM
dbacp05840 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 45% apoptosis at 20 µM
dbacp05841 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 65% apoptosis at 50 µM
dbacp05842 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 25% apoptosis at 10 µM
dbacp05843 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 66% apoptosis at 20 µM
dbacp05844 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 68% apoptosis at 50 µM
dbacp05845 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 43% apoptosis at 10 µM
dbacp05846 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 46% apoptosis at 20 µM
dbacp05847 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 79% apoptosis at 50 µM
dbacp05848 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 23% apoptosis at 10 µM
dbacp05849 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 35% apoptosis at 20 µM
dbacp05850 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 55% apoptosis at 50 µM
dbacp05851 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 1% apoptosis at 10 µM
dbacp05852 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 2% apoptosis at 20 µM
dbacp05853 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 3% apoptosis at 50 µM
dbacp05854 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 2% apoptosis at 10 µM
dbacp05855 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 1% apoptosis at 20 µM
dbacp05856 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 5% apoptosis at 50 µM
dbacp05857 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 1% apoptosis at 10 µM
dbacp05858 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 2% apoptosis at 20 µM
dbacp05859 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 3% apoptosis at 50 µM
dbacp05860 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 0% apoptosis at 10 µM
dbacp05861 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 1% apoptosis at 20 µM
dbacp05862 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 2% apoptosis at 50 µM
dbacp06023 Sansalv amide A NA Synthetic Peptide Apoptosis Cell viability assay S2-13 Pancreatic cancer EC50 : 7.5 µM
dbacp06169 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer Not found
dbacp06171 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : 8.1 ± 0.8 µM
dbacp06172 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : 5.6 ± 0.5 µM
dbacp06173 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer IC50 : >100 µM
dbacp06174 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay KB Oral cancer IC50 : >100 µM
dbacp06175 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : >100 µM
dbacp06176 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : >100 µM
dbacp06177 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Calu-6 Lung cancer 35% survival rate at 10 µM
dbacp06178 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Calu-6 Lung cancer 0% survival rate at 100 µM
dbacp06179 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Jurkat Blood cancer ~60% survival rate at 10 µM
dbacp06180 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Jurkat Blood cancer 0% survival rate at 100 µM
dbacp06181 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay SNU-601 Gastric cancer ~20% survival rate at 10 µM
dbacp06182 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay SNU-601 Gastric cancer 0% survival rate at 100 µM
dbacp06183 t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) RKKRRQRRRLNLKALLAVAKKIL Synthetic construct Apoptosis inducing MTT assay H157 Non-small cell Lung cancer IC50 : 2.79 μM
dbacp06184 t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) RKKRRQRRRLNLKALLAVAKKIL Synthetic construct Apoptosis inducing MTT assay MBD-MB-435S Melanocyte IC50 : 3.86 μM
dbacp06185 t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) RKKRRQRRRLNLKALLAVAKKIL Synthetic construct Apoptosis inducing MTT assay PC-3 Human prostate carcinoma IC50 : 3.86 μM
dbacp06186 t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) RKKRRQRRRLNLKALLAVAKKIL Synthetic construct Apoptosis inducing MTT assay U251-MG Human glioblastoma astrocytoma IC50 : 3.36 μM
dbacp06187 t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) RKKRRQRRRLNLKALLAVAKKIL Synthetic construct Apoptosis inducing MTT assay MCF-7 Human breast cancer IC50 : 3.70 μM
dbacp06196 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90 - 100% viablity
dbacp06197 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 10 µM 80% viablity
dbacp06198 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 100 µM 60% viablity
dbacp06293 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 0.96 nM
dbacp06294 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 1.30 nM
dbacp06295 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 0.64 nM
dbacp06346 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 1.70 nM
dbacp06347 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 3.88 nM
dbacp06348 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 3.00 nM
dbacp06404 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 49.4% Cytotoxic at 0.1 µg/ml
dbacp06405 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 51.2% Cytotoxic at 1 µg/ml
dbacp06406 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 53.0% Cytotoxic at 10 µg/ml
dbacp06407 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 61.2% Cytotoxic at 100 µg/ml
dbacp06408 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 39.0% Cytotoxic at 0.1 µg/ml
dbacp06409 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 20.8% Cytotoxic at 1 µg/ml
dbacp06410 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 33.8% Cytotoxic at 10 µg/ml
dbacp06411 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 35.6% Cytotoxic at 100 µg/ml
dbacp06548 Z1 KAAKKWAKAAKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06549 Z1 KAAKKWAKAAKKWAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 186 µM
dbacp06550 Z1 KAAKKWAKAAKKWAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : > 211 µM
dbacp06551 Z10 AAKKWAKAKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06552 Z10 AAKKWAKAKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : > 211 µM
dbacp06553 Z10 AAKKWAKAKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : > 211 µM
dbacp06554 Z2 KAAKKWAKAWKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06555 Z2 KAAKKWAKAWKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 173 µM
dbacp06556 Z2 KAAKKWAKAWKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : > 211 µM
dbacp06567 Z3 KAAKKAWKAWKKAAKAAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : >211 µM
dbacp06568 Z3 KAAKKAWKAWKKAAKAAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 128 µM
dbacp06569 Z3 KAAKKAWKAWKKAAKAAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : >211 µM
dbacp06570 Z4 KAAKKAWKAAKKAAKWWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 155 µM
dbacp06571 Z4 KAAKKAWKAAKKAAKWWKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 68 µM
dbacp06572 Z4 KAAKKAWKAAKKAAKWWKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 173 µM
dbacp06583 Z5 KAAKKAWKWAKKAAKWAKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 42 µM
dbacp06584 Z5 KAAKKAWKWAKKAAKWAKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 28 µM
dbacp06585 Z5 KAAKKAWKWAKKAAKWAKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 67 µM
dbacp06586 Z6 KWWKKAAKAAKKAAKAAKKWA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 17 µM
dbacp06587 Z6 KWWKKAAKAAKKAAKAAKKWA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 16 µM
dbacp06588 Z6 KWWKKAAKAAKKAAKAAKKWA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 31 µM
dbacp06589 Z7 KAAKKAWKAAKKAWKAAKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 15 µM
dbacp06590 Z7 KAAKKAWKAAKKAWKAAKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 15 µM
dbacp06591 Z7 KAAKKAWKAAKKAWKAAKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 21 µM
dbacp06592 Z8 AWKKWAKAWKWAKAKWWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 19 µM
dbacp06593 Z8 AWKKWAKAWKWAKAKWWAKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 14 µM
dbacp06594 Z8 AWKKWAKAWKWAKAKWWAKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 23 µM
dbacp06595 Z9 AAWKWAWAKKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 9 µM
dbacp06596 Z9 AAWKWAWAKKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 16 µM
dbacp06597 Z9 AAWKWAWAKKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 13 µM
dbacp06639 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 64.15 µg/mL
dbacp06640 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 44.76 µg/mL
dbacp06641 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 110.59 µg/mL
dbacp06642 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 67.34 µg/mL
dbacp06643 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 35.75 µg/mL
dbacp06644 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 10.38 µg/mL
dbacp06645 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 50.72 µg/mL
dbacp06646 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 58.63 µg/mL
dbacp06647 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 160.62 µg/mL
dbacp06648 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 66.43 µg/mL
dbacp06649 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 35.22 µg/ mL
dbacp06650 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 12.63 µg/mL
dbacp06651 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay NCI-H2122 NSCLC IC50 = 1.4 ± 0.3 nmol/L
dbacp06652 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay MiaPaCa.2 Pancreatic Cancer IC50 = 1.4 ± 0.2 nmol/L
dbacp06653 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay NCI-H441 NSCLC IC50 = 2.9 ± 0.7 nmol/L
dbacp06654 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay LS 180 Colon Cancer IC50 = 2.7 ± 0.4 nmol/L
dbacp06655 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay GSU Stomach Cancer IC50 = 0.17 ± 0.02 nmol/L
dbacp06659 Ahx-[Pal] Ahx-RWQWRWQWR Synthetic Apoptosis inducing MTT assay HT-29 Colon Cancer IC50 = 119 μM
dbacp06660 Ahx-[Pal] Ahx-RWQWRWQWR Synthetic Apoptosis inducing MTT assay CaCo-2 Colorectal Cancer IC50 = 40 μM
dbacp06661 9[Orn] [Pal] RWQWRWQWO Synthetic Apoptosis inducing MTT assay HT-29 Colon Cancer IC50 = 109 μM
dbacp06662 9[Orn] [Pal] RWQWRWQWO Synthetic Apoptosis inducing MTT assay CaCo-2 Colorectal Cancer IC50 = 40 μM
dbacp06663 9[Orn] [Pal] RWQWRWQWO Synthetic Apoptosis inducing MTT assay DU-145 Prostrate Cancer IC50 = 62 μM
dbacp06664 CH3CO-Ahx-[Pal] CH3-CO-Ahx-RWQWRWQWR Synthetic Apoptosis inducing MTT assay CaCo-2 Colorectal Cancer IC50 = 31 μM
dbacp06665 1[dR][Pal] rWQWRWQWR Synthetic Apoptosis inducing MTT assay CaCo-2 Colorectal Cancer IC50 = 105 μM
dbacp06666 1[Orn] [Pal] OWQWRWQWR Synthetic Apoptosis inducing MTT assay CaCo-2 Colorectal Cancer IC50 = 91 μM
dbacp06667 5[Orn] [Pal] RWQWOWQWR Synthetic Apoptosis inducing MTT assay CaCo-2 Colorectal Cancer IC50 = 64 μM
dbacp06668 1[dR] 5[Orn] [Pal] rWQWOWQWR Synthetic Apoptosis inducing MTT assay CaCo-2 Colorectal Cancer IC50 = 109 μM
dbacp06674 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 11.40 μM
dbacp06675 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 17.98 μM
dbacp06676 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 25.09 μM
dbacp06677 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 47.02 μM
dbacp06678 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 20.26 μM
dbacp06679 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 22.55 μM
dbacp06680 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 20.58 μM
dbacp06681 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 23.51 μM
dbacp06682 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 42.88 μM
dbacp06683 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 23.18 μM
dbacp06684 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 4.637 μM
dbacp06685 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 3.944 μM
dbacp06686 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 12.40 μM
dbacp06687 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 2.810 μM
dbacp06688 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 3.459 μM
dbacp06689 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 31.51 μM
dbacp06690 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 15.87 μM
dbacp06691 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 62.17 μM
dbacp06692 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 30.29 μM
dbacp06693 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 33.85 μM
dbacp06694 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 41.31 μM
dbacp06695 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 28.78 μM
dbacp06696 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 52.01 μM
dbacp06697 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 29.90 μM
dbacp06698 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 32.51 μM
dbacp06699 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 32.32 μM
dbacp06700 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 22.37 μM
dbacp06701 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 17.70 μM
dbacp06702 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 16.29 μM
dbacp06703 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 12.29 μM
dbacp06737 Aurein 1.2_mutant (Aurm) GLFDIIKKIIKSF Synthetic Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane MTT assay SW-480 Colon Cancer 51.63% cell viability
dbacp06738 Aurein 1.2_mutant (Aurm) GLFDIIKKIIKSF Synthetic Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane MTT assay HT-29 Colon Cancer 66.10% cell viability
dbacp06739 Aurein 1.2_R5 (R5-Aur) RRRRRGLFDIIKKIAESF Synthetic Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane MTT assay SW-480 Colon Cancer 43.89% cell viability
dbacp06740 Aurein 1.2_R5 (R5-Aur) RRRRRGLFDIIKKIAESF Synthetic Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane MTT assay HT-29 Colon Cancer 61.56% cell viability
dbacp06741 Aurein 1.2_mutant_R5 (R5-Aurm) RRRRRGLFDIIKKIIKSF Synthetic Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane MTT assay SW-480 Colon Cancer 40.62% cell viability
dbacp06742 Aurein 1.2_mutant_R5 (R5-Aurm) RRRRRGLFDIIKKIIKSF Synthetic Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane MTT assay HT-29 Colon Cancer 54.22% cell viability
dbacp06743 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay MDA-MB-231 Breast Cancer IC50 = 18.15 µM
dbacp06744 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay MCF-7 Breast Cancer IC50 = 31.05 µM
dbacp06745 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay ZR-75-30 Breast Cancer IC50 = 23.57 µM
dbacp06746 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay HeLa Cervical Cancer IC50 = 42.95 µM
dbacp06747 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay U-2 OS Bone Cancer IC50 = 25.65 µM
dbacp06748 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay A-549 Lung Cancer IC50 = 32.47 µM
dbacp06749 mPNC-NLS QETFSDLWKLLVQRKRQKLMP Synthetic p53-mediated apoptosis MTT assay A-549 Lung Cancer IC50 = 44.9 μM
dbacp06750 mPNC-NLS QETFSDLWKLLVQRKRQKLMP Synthetic p53-mediated apoptosis MTT assay U-87 Brain Tumor IC50 = 56.9 μM
dbacp06751 mPNC-NLS QETFSDLWKLLVQRKRQKLMP Synthetic p53-mediated apoptosis Cytotoxicity assay A-549 Lung Cancer IC50 = 45 μM
dbacp06754 37-mer peptide TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC Synthetic Apoptosis inducing MTT assay SNU-449 Liver Cancer IC50 = 76.4 ± 0.6015 μM
dbacp06755 37-mer peptide TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 33.65 ± 1.09 μM
dbacp06756 37-mer peptide TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC Synthetic Apoptosis inducing MTT assay SK-OV-3 Ovarian cancer IC50 = 27.45 ± 1.5085 μM
dbacp06757 ATMP5 THPPTTTTTTTTTTTYTAAPATTT Synthetic Analog of ATMP1 Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 64.04 ± 0.021 μg /ml
dbacp06763 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay MDA-MB-231 Breast Cancer IC50 = 24.25 µM
dbacp06764 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay 5637 Bladder cancer IC50 = 9.33 µM
dbacp06765 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay HeLa Cervical Cancer IC50 = 31.83 µM
dbacp06766 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay 786-0 Renal Cancer IC50 = 13.5 µM
dbacp06767 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay HCT-116 Colon Cancer IC50 = 9.08 µM
dbacp06768 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay A-549 Lung Cancer IC50 = 22.00 µM
dbacp06769 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay U-251 BrainTumor IC50 = 18.17 µM
dbacp06770 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay ZR-75-30 Breast Cancer IC50 = 12.92 µM
dbacp06774 PMAP-NC RIIDRLWLVRRPQKPKFVLVWVL Synthetic Analgog of PMAP-23 Membrane permeabilization MTT assay MDA-MB-361 Breast Cancer IC50 = 6.4 μM
dbacp06775 PMAP-NC RIIDRLWLVRRPQKPKFVLVWVL Synthetic Analgog of PMAP-24 Membrane permeabilization MTT assay A-549 Lung Cancer IC50 = 7.1 μM
dbacp06777 BK-1 rRP-Hyp-G-Thi-S-Apc-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06778 BK-2 rRP-Hyp-G-Thi-S-f-Apc-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06779 BK-3 Aaa-rRP-Hyp-G-Thi-S-Acc-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06780 BK-4 Aaa-rRP-Hyp-G-Thi-S-f-Acc-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06781 BK-5 rRP-Hyp-G-Thi-S-f-(L)Pip-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06782 BK-6 Aaa-rRP-Hyp-G-Thi-S-(D)Pip-(L)Pip-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06783 BK-7 rRP-Hyp-G-Thi-S-(D)Pip-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06784 BK-8 Aaa-rRP-Hyp-G-Thi-S-(D)Pip-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06785 NT-9 RRPYIL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06786 NT-10 RRPAIL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06787 NT-11 RRPYAL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06788 NT-12 PEGRKPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06789 NT-12 PEGKRPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06790 NT-12 PEGKKPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06796 LHRH-BinBC QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT Synthetic Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 10.96 μM
dbacp06797 LHRH-BinBC QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT Synthetic Apoptosis inducing LDH leakage assay MCF-7 Breast Cancer 40% LDH efflux at 16 µM
dbacp06803 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 46.2 ± 7.6 μM
dbacp06804 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 2.3 ± 0.2 μM
dbacp06805 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 36.2 ± 2.8 μM
dbacp06806 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 29.0 ± 3.7 μM
dbacp06807 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 6.4 ± 0.6 μM
dbacp06808 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 33.3 ±7.4μM
dbacp06809 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 26.5 ± 2.4 μM
dbacp06810 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 2.0 ± 0.1 μM
dbacp06811 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 20.9 ± 1.4 μM
dbacp06812 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 15.2 ± 1.9 μM
dbacp06813 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 1.3 ± 0.1 μM
dbacp06814 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 15.7 ±1.1μM
dbacp06815 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 22.5 ± 3.3 μM
dbacp06816 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 3.0 ± 0.1 μM
dbacp06817 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 51.5 ± 3.9 μM
dbacp06818 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 3.9 ± 0.2 μM
dbacp06819 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 51.0 ± 4.6 μM
dbacp06820 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 4.6 ± 0.2 μM
dbacp06821 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 > 64 μM
dbacp06822 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 37.5 ± 3.3 μM
dbacp06823 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 1.4 ± 0.2 μM
dbacp06824 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 38.5 ± 4.8 μM
dbacp06825 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 19.5 ± 0.5 μM
dbacp06826 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 1.7 ± 0.1 μM
dbacp06827 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 44.2 ± 2.2μM
dbacp06828 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 6.7 ± 0.7 μM
dbacp06829 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 2.1 ± 0.2 μM
dbacp06830 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 9.0 ± 1.1μM
dbacp06831 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 > 64 μM
dbacp06832 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 10.3 ± 1.1 μM
dbacp06833 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 > 64 μM
dbacp06834 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 48.4 ± 0.7 μM
dbacp06835 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 11.5 ± 0.6 μM
dbacp06836 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 34.1 ± 3.9 μM
dbacp06837 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 31.6 ± 1.3 μM
dbacp06838 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 5.4 ± 0.3 μM
dbacp06839 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 41.0 ± 4.2 μM
dbacp06840 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 15.1 ± 1.4 μM
dbacp06841 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 3.9 ± 0.1 μM
dbacp06861 LK-LE1 CLKKLLKLLKKLLKLCLHELLEHLHELLEH Synthetic Membrane disruption MTT assay HeLa Cervical Cancer IC50 = 11.3 µM at pH 6
dbacp06862 LK-LE2 CLKKLLKLLKKLLKLCLEHLLEHLEHLLEH Synthetic Membrane disruption MTT assay HeLa Cervical Cancer IC50 = 12.9 µM at pH 6
dbacp06863 LK-LE3 CLKKLLKLLKKLLKLCLEELLHHLEELLHH Synthetic Membrane disruption MTT assay HeLa Cervical Cancer IC50 = 10.2 µM at pH 6
dbacp06871 RR-1-RR RRWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 58 µM
dbacp06872 RR-1-RR RRWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 67 µM
dbacp06873 R-1-RR RWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 122 µM
dbacp06874 R-1-RR RWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 95 µM
dbacp06875 RR-1-R RRWQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 68 µM
dbacp06876 RR-1-R RRWQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 73 µM
dbacp06877 1 WQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 105 µM
dbacp06878 1 WQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 170 µM
dbacp06879 R-1 RWQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 58 µM
dbacp06880 R-1 RWQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 150 µM
dbacp06881 1-R WQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 130 µM
dbacp06882 1-R WQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 150 µM
dbacp06903 CIGB-300 GRKKRRQRRRPPQ-X-CWMSPRHLGTC Synthetic Cell Penetration Crystal Violet assay NCI-H-460 Lung Cancer IC50 = 30 ± 5.3 µM
dbacp06908 LFchimera FKCRRWQWRMKKLG-K-RSKNKGFKEQAKSLLKWILD Synthetic - Lectoferrin chimera Apoptosis inducing MTT assay HepG-2 Liver Cancer cell viability ~ 44% at 10 µM
dbacp06909 LFchimera FKCRRWQWRMKKLG-K-RSKNKGFKEQAKSLLKWILD Synthetic - Lectoferrin chimera Apoptosis inducing MTT assay Jurkat Blood Cancer cell viability ~ 8% at 20 µM
dbacp06910 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay MDA-MB-231 Breast Cancer 33.6% decrease in cell viability at 10 μM
dbacp06911 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay HeLa Cervical Cancer 30.2 % decrease in cell viability at 10 μM
dbacp06912 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay A-549 Lung Cancer 17.4% decrease in cell viability at 10 μM
dbacp06913 AC-P19M FAKKLAKLKKKLAKLAKKR Synthetic analogue of AC-P19 Inhibition of cell signalling WST-8 assay A-549 Lung Cancer IC50 = 9.84 µM
dbacp06914 AC-P19M FAKKLAKLKKKLAKLAKKR Synthetic analogue of AC-P19 Inhibition of cell signalling WST-8 assay H-460 Lung Cancer IC50 = 6.29 µM
dbacp06915 AC-P19 FAKKLAKLKKKLAKLALAL Synthetic Inhibition of cell signalling WST-8 assay A-549 Lung Cancer IC50 = 52.14 µM
dbacp06916 AC-P19 FAKKLAKLKKKLAKLALAL Synthetic Inhibition of cell signalling WST-8 assay H-460 Lung Cancer IC50 = 49.08 µM
dbacp06917 KM8 KLLKINLKALAALAKKIL Synthetic derivative of Mastoparan Apoptosis inducing Not Available Not Available Not Available Not Available
dbacp06918 KM8-Aib KLLKINLK(Aib)LAALAKKIL Synthetic derivative of KM8 Apoptosis inducing Not Available Not Available Not Available Not Available
dbacp06920 HAZ GVKFAKRFWRFAKKAFKRFEK Synthetic Cell membrane destabilization MTT assay A-549 Lung Cancer IC50 = 5.44 μM
dbacp06975 C16-E4Y EEEEY Synthetic Inhibition of cell signalling WST-8 assay A-431 Skin Cancer 10 % cell viability at 0.05 wt %
dbacp06976 C16-E4Y EEEEY Synthetic Inhibition of cell signalling WST-8 assay HeLa Cervical Cancer 60% cell viability at 0.05 wt %
dbacp06977 C16-E4Y EEEEY Synthetic Inhibition of cell signalling WST-8 assay HepG-2 Liver Cancer 50 % cell viability at 0.05 wt %
dbacp06978 C16-E4Y EEEEY Synthetic Inhibition of cell signalling WST-8 assay MCF-7 Breast Cancer 50 % cell viability at 0.05 wt %
dbacp06980 Ponericin-W1 (11-25), At1 KLLPSVVGLFKKKKQ Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 > 100 µM
dbacp06981 Ponericin-W1 (11-25), At1 KLLPSVVGLFKKKKQ Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 >100 µM
dbacp06982 Ponericin-W1 (11-25) [P4K KLLKKVVKLFKKKKK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 >100 µM
dbacp06983 Ponericin-W1 (11-25) [P4K KLLKKVVKLFKKKKK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 >100 µM
dbacp06984 Ponericin-W1 (11-25) [P4K KLLKKVVKLFKKLLK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 4.3 µM
dbacp06985 Ponericin-W1 (11-25) [P4K KLLKKVVKLFKKLLK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 2.2 µM
dbacp06986 At4 KLLKKLLKLLKKLLK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 7.2 µM
dbacp06987 At4 KLLKKLLKLLKKLLK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 2.5 µM
dbacp06988 At5 KIIKKIIKIIKKIIK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 3.6 µM
dbacp06989 At5 KIIKKIIKIIKKIIK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 1.5 µM
dbacp06990 At6 KVVKKVVKVVKKVVK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 > 100 µM
dbacp06991 At6 KVVKKVVKVVKKVVK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 70.8 µM
dbacp06992 At7 KIIKKIKKKIKKIIK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 10.3 µM
dbacp06993 At7 KIIKKIKKKIKKIIK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 8.8 µM
dbacp06994 At8 KLLKKLKKKLKKLLK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 13.4 µM
dbacp06995 At8 KLLKKLKKKLKKLLK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 8.9 µM
dbacp06996 At9 KVVKKVKKKVKKVVK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 100 µM
dbacp06997 At9 KVVKKVKKKVKKVVK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 51.7 µM
dbacp06998 At10 IKKIIKIIKKIIKKI Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 4.4 µM
dbacp06999 At10 IKKIIKIIKKIIKKI Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 3.2 µM
dbacp07000 At11 IIIKKIKKKIKKIII Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 7.9 µM
dbacp07001 At11 IIIKKIKKKIKKIII Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 7.6 µM
dbacp07002 At12 KIIIKIKKKIKIIIK Synthetic Apoptosis inducing MTT assay A-549 Lung Cancer IC50 = 14.0 µM
dbacp07003 At12 KIIIKIKKKIKIIIK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 13.4 µM
dbacp07006 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay U-251 Brain Tumor mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07007 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay MCF-7 Breast Cancer mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07008 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay A-375 Skin Cancer mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07009 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay DU-145 Prostate Cancer mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07010 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay A-549 Lung Cancer mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07011 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay T98G Brain Tumor mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07017 D-LAK-120-A kklalalakkwlalakklalalakk Synthetic ROS induction, mitochondria-mediated apoptosis. MTT assay A-549 Lung Cancer IC50 = 5.55 ± 0.13 μM
dbacp07018 D-LAK-120-A kklalalakkwlalakklalalakk Synthetic ROS induction, mitochondria-mediated apoptosis. MTT assay H-358 Non Small Cell Lung Cancer (NSCLC) IC50 = 4.00 ± 0.20 μM
dbacp07019 D-LAK-120-A kklalalakkwlalakklalalakk Synthetic ROS induction, mitochondria-mediated apoptosis. MTT assay H-1975 Non Small Cell Lung Cancer (NSCLC) IC50 between 4.0 and 5.5 μM
dbacp07020 D-LAK-120-A kklalalakkwlalakklalalakk Synthetic ROS induction, mitochondria-mediated apoptosis. MTT assay HCC-827 Lung Adenocarcinoma IC50 between 4.0 and 5.5 μM
dbacp07055 Temporin-PKE-2K FLPLIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay U251-MG Brain Tumor IC50 = 2.49 μM
dbacp07056 Temporin-PKE-2K FLPLIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay PC-3 Prostate Cancer IC50 = 2.64 μM
dbacp07057 Temporin-PKE-2K FLPLIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-838 Lung Cancer IC50 = 3.07 μM
dbacp07058 Temporin-PKE-2K FLPLIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay HCT-116 Colorectal Cancer IC50 = 2.84 μM
dbacp07059 Temporin-PKE-2K FLPLIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-157 Lung Cancer IC50 = 2.78 μM
dbacp07060 Temporin-PKE-K12 FLPLIIGALSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay U251-MG Brain Tumor IC50 = 25.75 μM
dbacp07061 Temporin-PKE-K12 FLPLIIGALSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay PC-3 Prostate Cancer IC50 = 27.32 μM
dbacp07062 Temporin-PKE-K12 FLPLIIGALSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-838 Lung Cancer IC50 = 22.67 μM
dbacp07063 Temporin-PKE-K12 FLPLIIGALSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay HCT-116 Colorectal Cancer IC50 = 22.09 μM
dbacp07064 Temporin-PKE-K12 FLPLIIGALSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-157 Lung Cancer IC50 = 24.03 μM
dbacp07065 Temporin-PKE-3K FLPKIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay U251-MG Brain Tumor IC50 = 2.83 μM
dbacp07066 Temporin-PKE-3K FLPKIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay PC-3 Prostate Cancer IC50 = 3.01 μM
dbacp07067 Temporin-PKE-3K FLPKIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-838 Lung Cancer IC50 = 0.51 μM
dbacp07068 Temporin-PKE-3K FLPKIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay HCT-116 Colorectal Cancer IC50 = 0.38 μM
dbacp07069 Temporin-PKE-3K FLPKIIGKLSSLLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-157 Lung Cancer IC50 = 3.29 μM
dbacp07070 Temporin-PKE-4K FLPKIIGKLSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay U251-MG Brain Tumor IC50 = 85.52 μM
dbacp07071 Temporin-PKE-4K FLPKIIGKLSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay PC-3 Prostate Cancer IC50 = 49.50 μM
dbacp07072 Temporin-PKE-4K FLPKIIGKLSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-838 Lung Cancer IC50 = 35.28 μM
dbacp07073 Temporin-PKE-4K FLPKIIGKLSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay HCT-116 Colorectal Cancer IC50 = 99.36 μM
dbacp07074 Temporin-PKE-4K FLPKIIGKLSSKLPKIF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-157 Lung Cancer IC50 = 27.76 μM
dbacp07075 Temporin-PKE-i FLPLIIGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay U251-MG Brain Tumor IC50 = 4.46 μM
dbacp07076 Temporin-PKE-i FLPLIIGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay PC-3 Prostate Cancer IC50 = 3.35 μM
dbacp07077 Temporin-PKE-i FLPLIIGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-838 Lung Cancer IC50 = 5.28 μM
dbacp07078 Temporin-PKE-i FLPLIIGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay HCT-116 Colorectal Cancer IC50 = 3.07 μM
dbacp07079 Temporin-PKE-i FLPLIIGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-157 Lung Cancer IC50 = 2.94 μM
dbacp07080 Temporin-PKE-3i FLPLiiGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay U251-MG Brain Tumor IC50 = 120.6 μM
dbacp07081 Temporin-PKE-3i FLPLiiGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay PC-3 Prostate Cancer IC50 = 167 μM
dbacp07082 Temporin-PKE-3i FLPLiiGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-838 Lung Cancer IC50 = 193.4 μM
dbacp07083 Temporin-PKE-3i FLPLiiGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay HCT-116 Colorectal Cancer IC50 = 72.06 μM
dbacp07084 Temporin-PKE-3i FLPLiiGALSSLLPKiF Synthetic Charge-optimized membranolysis induces apoptosis. MTT assay H-157 Lung Cancer IC50 = 71.18 μM
dbacp07085 HB43 FAKLLAKLAKKLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay SW-480 Colon Cancer IC50 = 12 ± 4 μM
dbacp07086 HB43 FAKLLAKLAKKLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay SW-620 Colon Cancer IC50 = 10 ± 1 μM
dbacp07087 HB43 FAKLLAKLAKKLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay HT-29 Colon Cancer IC50 = 11 ± 1 μM
dbacp07088 HB43 FAKLLAKLAKKLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay MDA-MB-231 Breast Cancer 50% cell viability at 20 μM
dbacp07089 HB43-mut2 FAKLLAKLAKLLK Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay SW-480 Colon Cancer IC50 = 34 ± 2 μM
dbacp07090 HB43-mut2 FAKLLAKLAKLLK Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay SW-620 Colon Cancer IC50 = 40 ± 3 μM
dbacp07091 HB43-mut2 FAKLLAKLAKLLK Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay HT-29 Colon Cancer IC50 = 50 ± 3 μM
dbacp07092 HB43-mut2 FAKLLAKLAKLLK Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay MDA-MB-231 Breast Cancer 80% cell viability at 20 μM
dbacp07093 HB43-mut3 FAKLLAKLARRLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay SW-480 Colon Cancer IC50 = 8 ± 1 μM
dbacp07094 HB43-mut3 FAKLLAKLARRLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay SW-620 Colon Cancer IC50 = 9 ± 1 μM
dbacp07095 HB43-mut3 FAKLLAKLARRLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay HT-29 Colon Cancer IC50 = 9 ± 1 μM
dbacp07096 HB43-mut3 FAKLLAKLARRLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay MDA-MB-231 Breast Cancer 75% cell viability at 20 μM
dbacp07097 K2F6K2 KKFFFFFFKK Synthetic Positive charge–driven membrane disruption apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 1146.23 ± 346.83 μg/mL
dbacp07098 K3F6K3 KKKFFFFFFKKK Synthetic Positive charge–driven membrane disruption apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 123.10 ± 35.19 μg/mL
dbacp07099 K4F6K4 KKKKFFFFFFKKKK Synthetic Positive charge–driven membrane disruption apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 62.64 ± 9.55 μg/mL
dbacp07100 K4F6K4 KKKKFFFFFFKKKK Synthetic Positive charge–driven membrane disruption apoptosis AnnexinV-FITC/PI double staining assay A-549 Lung Cancer apoptotic cells (early and late) increased from 9.59 ± 1.00% to 43.03 ± 2.13%
dbacp07101 K4F8K4 KKKKFFFFFFFFKKKK Synthetic Positive charge–driven membrane disruption apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 571.87 ± 66.23 μg/mL
dbacp07107 Nigrocin-M1 GLLGKILGAGKKVLLGVSGLL Synthetic Membrane disruption mediates selective cytotoxicity. MTT assay H-157 Non-small cell lung cancer IC50 = 24 μM
dbacp07108 Nigrocin-M1 GLLGKILGAGKKVLLGVSGLL Synthetic Membrane disruption mediates selective cytotoxicity. MTT assay PC-3 Prostate cancer IC50 = 31.27 μM
dbacp07109 Nigrocin-M1 GLLGKILGAGKKVLLGVSGLL Synthetic Membrane disruption mediates selective cytotoxicity. MTT assay U-251-MG Brain Tumor IC50 = 25.06 μM
dbacp07110 Nigrocin-M1 GLLGKILGAGKKVLLGVSGLL Synthetic Membrane disruption mediates selective cytotoxicity. MTT assay MCF-7 Breast Cancer IC50 = 24.60 μM
dbacp07111 LyeTx-I-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Synergistic autophagic death via AKT inhibition. MTT assay MDA-MB-231 Breast Cancer IC50 = 2.47 µM
dbacp07117 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay MCF-7 Breast Cancer IC50 = 5.85 ± 1.28 µg/ml
dbacp07118 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay HepG-2 Liver Cancer IC50 = 7.57 ± 0.17 µg/ml
dbacp07119 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 17.81 ± 0.6 µg/ml
dbacp07120 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay HeLa Cervical Cancer IC50 = 11.56 ± 0.65 µg/ml
dbacp07121 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay A-549 Lung Cancer IC50 = 4.92 ± 0.84 µg/ml
dbacp07122 DEE GLLDLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 5.55 ± 0.35 µM
dbacp07123 DEE GLLDLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 6.05 ± 2.76 µM
dbacp07124 DEE GLLDLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 61.00 ± 1.41 µM
dbacp07125 EEE GLLELLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 6.25 ± 1.77 µM
dbacp07126 EEE GLLELLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 10.55 ± 3.46 µM
dbacp07127 EEE GLLELLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 78.75 ± 5.30 µM
dbacp07128 HEE GLLHLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 6.50 ± 0.71 µM
dbacp07129 HEE GLLHLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 4.95 ± 0.49 µM
dbacp07130 HEE GLLHLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 47.50 ± 11 µM
dbacp07131 KEE GLLKLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.75 ± 0.78 µM
dbacp07132 KEE GLLKLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.05 ± 0.21 µM
dbacp07133 KEE GLLKLLELLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 49.38 ± 13.26 µM
dbacp07134 DHE GLLDLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.75 ± 0.92 µM
dbacp07135 DHE GLLDLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.80 ± 0.14 µM
dbacp07136 DHE GLLDLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 17.25 ± 1.06 µM
dbacp07137 EHE GLLELLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.90 ± 0.28 µM
dbacp07138 EHE GLLELLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.55 ± 0.07 µM
dbacp07139 EHE GLLELLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 18.25 ± 1.06 µM
dbacp07140 HHE GLLHLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 16.70 ± 2.26 µM
dbacp07141 HHE GLLHLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 10.75 ± 0.78 µM
dbacp07142 HHE GLLHLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 53.25 ± 5.30 µM
dbacp07143 KHE GLLKLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.70 ± 0.14 µM
dbacp07144 KHE GLLKLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.92 ± 0.17 µM
dbacp07145 KHE GLLKLLHLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 53 ± 2.83 µM
dbacp07146 DKE GLLDLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 2.10 ± 0 µM
dbacp07147 DKE GLLDLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.57 ± 0.33 µM
dbacp07148 DKE GLLDLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 9.93 ± 0.25 µM
dbacp07149 EKE GLLELLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.80 ± 0.28 µM
dbacp07150 EKE GLLELLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.30 ± 0.14 µM
dbacp07151 EKE GLLELLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 8.00 ± 0.71 µM
dbacp07152 HKE GLLHLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 2.70 ± 0.28 µM
dbacp07153 HKE GLLHLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.90 ± 0.42 µM
dbacp07154 HKE GLLHLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 15.95 ± 0.78 µM
dbacp07155 KKE GLLKLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 2.05 ± 0.64 µM
dbacp07156 KKE GLLKLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.70 ± 0 µM
dbacp07157 KKE GLLKLLKLLLEAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 12.75 ± 1.20 µM
dbacp07158 DEH GLLDLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 5.35 ± 1.91 µM
dbacp07159 DEH GLLDLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 3.60 ± 0.42 µM
dbacp07160 DEH GLLDLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 36.48 ± 3.92 µM
dbacp07161 EEH GLLELLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.30 ± 0.14 µM
dbacp07162 EEH GLLELLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 3.60 ± 0.85 µM
dbacp07163 EEH GLLELLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 19.60 ± 3.96 µM
dbacp07164 HEH GLLHLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 28.60 ± 10.75 µM
dbacp07165 HEH GLLHLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 10.95 ± 1.06 µM
dbacp07166 HEH GLLHLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 106 ± 14 µM
dbacp07167 KEH GLLKLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.30 ± 0.42 µM
dbacp07168 KEH GLLKLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.35 ± 0.07 µM
dbacp07169 KEH GLLKLLELLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 49.25 ± 5.30 µM
dbacp07170 DHH GLLDLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 21.45 ± 2.47 µM
dbacp07171 DHH GLLDLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 11.90 ± 0.14 µM
dbacp07172 DHH GLLDLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 55.85 ± 18.88 µM
dbacp07173 EHH GLLELLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 25.35 ± 2.76 µM
dbacp07174 EHH GLLELLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 16.05 ± 3.18 µM
dbacp07175 EHH GLLELLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 117 ± 7 µM
dbacp07176 HHH GLLHLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 21.10 ± 6.93 µM
dbacp07177 HHH GLLHLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 9.50 ± 0.99 µM
dbacp07178 HHH GLLHLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 185 ± 7 µM
dbacp07179 KHH GLLKLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 5.20 ± 0.71 µM
dbacp07180 KHH GLLKLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 4.45 ± 0.49 µM
dbacp07181 KHH GLLKLLHLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 39.75 ± 5.30 µM
dbacp07182 DKH GLLDLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.45 ± 0.07 µM
dbacp07183 DKH GLLDLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.80 ± 0.28 µM
dbacp07184 DKH GLLDLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 21.13 ± 3.01 µM
dbacp07185 EKH GLLELLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 2.75 ± 0.07 µM
dbacp07186 EKH GLLELLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.18 ± 0.31 µM
dbacp07187 EKH GLLELLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 23.83 ± 0.81 µM
dbacp07188 HKH GLLHLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.45 ± 0.21 µM
dbacp07189 HKH GLLHLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 3.10 ± 0.57 µM
dbacp07190 HKH GLLHLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 18.88 ± 1.24 µM
dbacp07191 KKH GLLKLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 2.40 ± 0.85 µM
dbacp07192 KKH GLLKLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.20 ± 0.42 µM
dbacp07193 KKH GLLKLLKLLLHAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 13.30 ± 0.99 µM
dbacp07194 DEK GLLDLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.14 ± 0.52 µM
dbacp07195 DEK GLLDLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 0.70 ± 0.07 µM
dbacp07196 DEK GLLDLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 19.88 ± 2.65 µM
dbacp07197 EEK GLLELLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.10 ± 0.14 µM
dbacp07198 EEK GLLELLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.08 ± 0.18 µM
dbacp07199 EEK GLLELLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 32.88 ± 4.07 µM
dbacp07200 HEK GLLHLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 2.35 ± 1.06 µM
dbacp07201 HEK GLLHLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 3.45 ± 2.19 µM
dbacp07202 HEK GLLHLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 143.20 ± 80.33 µM
dbacp07203 KEK GLLKLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.60 ± 0.14 µM
dbacp07204 KEK GLLKLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.35 ± 0.07 µM
dbacp07205 KEK GLLKLLELLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 8.15 ± 0.49 µM
dbacp07206 DHK GLLDLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.75 ±0.49 µM
dbacp07207 DHK GLLDLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.02 ± 0.12 µM
dbacp07208 DHK GLLDLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 20.45 ± 2.05 µM
dbacp07209 EHK GLLELLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.35 ± 0.35 µM
dbacp07210 EHK GLLELLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 0.71 ± 0.13 µM
dbacp07211 EHK GLLELLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 25.00 ± 0 µM
dbacp07212 HHK GLLHLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.15 ± 0.07 µM
dbacp07213 HHK GLLHLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.75 ± 0.21 µM
dbacp07214 HHK GLLHLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 12.65 ± 1.91 µM
dbacp07215 KHK GLLKLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 2.59 ± 0.92 µM
dbacp07216 KHK GLLKLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.40 ± 0.14 µM
dbacp07217 KHK GLLKLLHLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 12.88 ± 1.24 µM
dbacp07218 DKK GLLDLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.95 ± 0.35 µM
dbacp07219 DKK GLLDLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.20 ± 0.14 µM
dbacp07220 DKK GLLDLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 10.40 ± 1.70 µM
dbacp07221 EKK GLLELLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.72 ± 0.21 µM
dbacp07222 EKK GLLELLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.19 ± 0.40 µM
dbacp07223 EKK GLLELLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 12.20 ± 1.84 µM
dbacp07224 HKK GLLHLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 3.40 ± 0.71 µM
dbacp07225 HKK GLLHLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 2.60 ± 0.42 µM
dbacp07226 HKK GLLHLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 12.23 ± 0.11 µM
dbacp07227 KKK GLLKLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 1.57 ± 0.24 µM
dbacp07228 KKK GLLKLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 1.35 ± 0.40 µM
dbacp07229 KKK GLLKLLKLLLKAAGW Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 9.65 ± 1.20 µM
dbacp07230 d-DHK GlldllhlllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 0.32 ± 0.07 µM
dbacp07231 d-DHK GlldllhlllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 0.23 ± 0.04 µM
dbacp07232 d-DHK GlldllhlllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 1.24 ± 0.03 µM
dbacp07233 d-DEK GlldllelllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 0.44 ± 0.10 µM
dbacp07234 d-DEK GlldllelllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 0.36 ± 0 µM
dbacp07235 d-DEK GlldllelllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 5.84 ± 0.04 µM
dbacp07236 d-EEK GllellelllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER Breast Cancer IC50 = 0.29 ± 0.01 µM
dbacp07237 d-EEK GllellelllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay HMLER-shEcad Breast Cancer IC50 = 0.29 ± 0.01 µM
dbacp07238 d-EEK GllellelllkaaGw Synthetic Selective membrane perforation prevents resistance. MTT assay U-2 OS Bone Cancer IC50 = 4.78 ± 0.02 µM
dbacp07244 CIGB-552 HARIKpTFRRlKWKYKGKFW Synthetic NF-κB inhibition enhances cisplatin synergy Sulforhodamine B assay NCI-H-460 Lung Cancer IC50 = 287.9 μM
dbacp07245 CIGB-552 HARIKpTFRRlKWKYKGKFW Synthetic NF-κB inhibition enhances cisplatin synergy Sulforhodamine B assay A-549 Lung Cancer IC50 = 44.6 μM
dbacp07246 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay U87-MG Brain Tumor IC50 = 4.3 ± 0.3 μM
dbacp07247 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay U-251 Brain Tumor IC50 = 4.9 ± 0.3 μM
dbacp07248 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay A-172 Brain Tumor IC50 = 6.4 ± 0.4 μM
dbacp07249 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay T98G Brain Tumor IC50 = 7.1 ± 0.2 μM
dbacp07250 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay U-373 Brain Tumor IC50 = 5.0 ± 0.2 μM
dbacp07251 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay U-118 Brain Tumor IC50 = 6.8 ± 0.2 μM
dbacp07252 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay D54 Brain Tumor IC50 = 8.4 ± 0.1 μM
dbacp07253 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay SW-1783 Brain Tumor IC50 = 4.8 ± 0.2 μM
dbacp07254 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay LN229 Brain Tumor IC50 = 4.7 ± 0.2 μM
dbacp07255 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay U-138 Brain Tumor IC50 = 7.5 ± 0.3 μM
dbacp07256 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay SF-268 Brain Tumor IC50 = 4.8 ± 0.1 μM
dbacp07257 ATX-101 MDRWLVKWKKKRKIRRRRRRRRRRR Synthetic PCNA interference disrupts DNA repair. CCK-8 assay SNB-19 Brain Tumor IC50 = 12.0 ± 0.6 μM
dbacp07258 trans-Phakellistatin 18 trans(P)PIPYPIF Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 67.5 ± 2.938 µM
dbacp07309 LyeTxI-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Apoptosis induction and immune modulation. MTT assay 4T1 Breast Cancer IC50 = 6.5 ± 5.30 µM
dbacp07310 LyeTxI-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Apoptosis induction and immune modulation. MTT assay MCF-7 Breast Cancer IC50 = 7.34 ± 3.09 µM
dbacp07311 LyeTxI-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Apoptosis induction and immune modulation. MTT assay MDA-MB-231 Breast Cancer IC50 = 5.77 ± 0.83 µM
dbacp07324 IK13 CIIKKIIKKIIKK Synthetic Mitochondrial mediated apoptosis MTT assay HCT-116 Colorectal Cancer IC50 = 29 ± 6 µM
dbacp07325 IK13 CIIKKIIKKIIKK Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 47±5 µM
dbacp07326 LK13 CLLKKLLKKLLKK Synthetic Mitochondrial mediated apoptosis MTT assay HCT-116 Colorectal Cancer IC50 = 23 ± 2 µM
dbacp07327 LK13 CLLKKLLKKLLKK Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 83 ± 9 µM
dbacp07328 IR13 CIIRRIIRRIIRR Synthetic Mitochondrial mediated apoptosis MTT assay HCT-116 Colorectal Cancer IC50 > 100 µM
dbacp07329 IR13 CIIRRIIRRIIRR Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 > 100 µM
dbacp07330 LR13 CLLRRLLRRLLRR Synthetic Mitochondrial mediated apoptosis MTT assay HCT-116 Colorectal Cancer IC50 = 15.6 ± 1.0 µM
dbacp07331 LR13 CLLRRLLRRLLRR Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 26.7 ± 1.3 µM
dbacp07332 CI-15 CIIKKIIKKIIKKII Synthetic Mitochondrial mediated apoptosis MTT assay HCT-116 Colorectal Cancer IC50 = 7.7 ± 0.2 µM
dbacp07333 CI-15 CIIKKIIKKIIKKII Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 2.7 ± 0.5 µM
dbacp07334 GI-15 LC-Propargyl-GIIKKIIKKIIKKII Synthetic Mitochondrial mediated apoptosis MTT assay HCT-116 Colorectal Cancer IC50 = 13.6 ± 0.2 µM
dbacp07335 GI-15 LC-Propargyl-GIIKKIIKKIIKKII Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 16.6 ± 0.8 µM
dbacp07339 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay A-549 Lung Cancer IC50 = 4.5 µM
dbacp07340 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay CT-26 Colorectal Cancer IC50 = 2.2 µM
dbacp07341 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay MDA-MB-435 WT Breast Cancer IC50 = 3.5 µM
dbacp07342 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay MDA-MB-435 DOX-R Breast Cancer IC50 = 3.4 µM
dbacp07347 GA - 2 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 7.70 ± 1.3 µg/mL
dbacp07348 GA - 2 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay HCT-116 Colon Cancer IC50 = 70.30 ± 0.9 µg/mL
dbacp07349 GA - 3 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 5.1 ± 0.7 µg/mL
dbacp07350 GA - 3 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay HCT-116 Colon Cancer IC50 = 7.40 ± 0.4 µg/mL
dbacp07351 GA - 4 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 6.10 ± 0.4 µg/mL
dbacp07352 GA - 4 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay HCT-116 Colon Cancer IC50 = 73.0 ± 1.4 µg/mL
dbacp07353 GA - 5 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 5.0 ± 0.3 µg/mL
dbacp07354 GA - 5 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay HCT-116 Colon Cancer IC50 = 5.2 ± 0.8 µg/mL
dbacp07355 GA - 7 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 3.70 ± 0.2 µg/mL
dbacp07356 GA - 7 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay HCT-116 Colon Cancer IC50 = 3.0 ± 1.1 µg/mL
dbacp07357 GA - 7 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay HepG-2 Liver Cancer IC50 = 3.30 ± 0.1 µg/mL
dbacp07358 GA - 8 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 6.90 ± 1.1 µg/mL
dbacp07359 GA - 8 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay HCT-116 Colon Cancer IC50 = 60.70 ± 0.6 µg/mL
dbacp07360 N-Ter-TAT RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Synthetic Mitochondrial targeting, VDAC1-HKII dissociation MTT assay A-375 Skin Cancer IC50 > 50.0 μM
dbacp07397 Pugnin A RLMRIFRILKLAR Synthetic Membrane disruption induces necrotic death MTT assay MCF-7 Breast Cancer 12% Cytotoxicity at 100 µM
dbacp07398 Pugnin A RLMRIFRILKLAR Synthetic Membrane disruption induces necrotic death MTT assay PC-3 Prostate Cancer 74% Cytotoxicity at 100 µM
dbacp07399 Pugnin B RMMRIFWVIKLAR Synthetic Membrane disruption induces necrotic death MTT assay MCF-7 Breast Cancer 5% Cytotoxicity at 100 µM
dbacp07400 Pugnin B RMMRIFWVIKLAR Synthetic Membrane disruption induces necrotic death MTT assay PC-3 Prostate Cancer 90% Cytotoxicity at 100 µM
dbacp07402 Pep GKLRLIKKLWVKKWKKKGWKA Synthetic Membrane disruption induces necrotic death MTT assay A-549 Lung Cancer IC50 = 4 µM
dbacp07403 Pep GKLRLIKKLWVKKWKKKGWKA Synthetic Membrane disruption induces necrotic death MTT assay MCF-7 Breast Cancer IC50 = 2 µM
dbacp07411 Si1 (KLAKLAK)2 Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 124.1 ± 8.12 µM
dbacp07412 Si1 (KLAKLAK)2 Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 746.5 ± 7.6 µM
dbacp07413 Si3 KL(Beta-A)KL(Beta-A)AK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 176.3 ± 4.66 µM
dbacp07414 Si2 KL(Beta-A)KL(Beta-A)K Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 662.9 ± 20.02 µM
dbacp07415 Si2 KL(Beta-A)KL(Beta-A)K Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 840 ± 21.18 µM
dbacp07416 Si11 KL(Beta-A)KL(Beta-A)K Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 1087 ± 70.71 µM
dbacp07417 Si11 KL(Beta-A)KLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 228.8 ± 7.18 µM
dbacp07418 Si13 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 1704 ± 112 µM
dbacp07419 Si14 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 593.3 ± 60.3 µM
dbacp07420 Si14 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 1049 ± 49.77 µM
dbacp07421 Si15 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 140.3 ± 7.12 µM
dbacp07422 Si15 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 346.3 ± 7.91 µM
dbacp07432 [Arg]3-VmCT1 FLRALWNVAKSVF Synthetic Membrane disruption via cationic interaction MTT assay MCF-7 Breast Cancer IC50 = 20.6 ± 3.1 μmol/L
dbacp07433 [Arg]7-VmCT1 FLGALWRVAKSVF Synthetic Membrane disruption via cationic interaction MTT assay MCF-7 Breast Cancer IC50 = 18.0 ± 2.7 μmol/L
dbacp07434 [Arg]11-VmCT1 FLGALWNVAKRVF Synthetic Membrane disruption via cationic interaction MTT assay MCF-7 Breast Cancer IC50 = 25.8 ± 5.2 μmol/L
dbacp07435 L9H5-1 LHLLLHLLHHLLHL Synthetic Acid-triggered membrane disruption apoptosis MTT assay HeLa Cervical Cancer IC50 = 5.4 µM
dbacp07436 L8H6 LHHLLHLLHHLLHL Synthetic Acid-triggered membrane disruption apoptosis MTT assay HeLa Cervical Cancer IC50 = 16.4 µM
dbacp07437 A4K14 - Citropin 1.1 - Sp 7 GLFAVR8KKVASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay C4-2B Prostate Cancer IC50 = 10.23 µM
dbacp07438 A4K14 - Citropin 1.1 - Sp 7 GLFAVR8KKVASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 16.37 µM
dbacp07439 A4K14 - Citropin 1.1 - Sp 7 GLFAVR8KKVASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay U-87 Brain Tumor IC50 = 14.72 µM
dbacp07440 A4K14 - Citropin 1.1 - Sp 7 GLFAVR8KKVASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 12.1 µM
dbacp07441 A4K14 - Citropin 1.1 - Sp 6 GR8FAVIKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay C4-2B Prostate Cancer IC50 = 35.84 µM
dbacp07442 A4K14 - Citropin 1.1 - Sp 6 GR8FAVIKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 30.19 µM
dbacp07443 A4K14 - Citropin 1.1 - Sp 6 GR8FAVIKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay U-87 Brain Tumor IC50 = 34.49 µM
dbacp07444 A4K14 - Citropin 1.1 - Sp 6 GR8FAVIKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 23.78 µM
dbacp07445 A4K14 - Citropin 1.1 - Sp 5 GLFAVIKKVAS5VIKS5L Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay C4-2B Prostate Cancer IC50 = 11.9 µM
dbacp07446 A4K14 - Citropin 1.1 - Sp 5 GLFAVIKKVAS5VIKS5L Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 9.899 µM
dbacp07447 A4K14 - Citropin 1.1 - Sp 5 GLFAVIKKVAS5VIKS5L Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay U-87 Brain Tumor IC50 = 8.229 µM
dbacp07448 A4K14 - Citropin 1.1 - Sp 5 GLFAVIKKVAS5VIKS5L Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 12.42 µM
dbacp07449 A4K14 - Citropin 1.1 - Sp 4 GLFAVIKKS5ASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay C4-2B Prostate Cancer IC50 = 8.9 µM
dbacp07450 A4K14 - Citropin 1.1 - Sp 4 GLFAVIKKS5ASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 10.51 µM
dbacp07451 A4K14 - Citropin 1.1 - Sp 4 GLFAVIKKS5ASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay U-87 Brain Tumor IC50 = 7.277 µM
dbacp07452 A4K14 - Citropin 1.1 - Sp 4 GLFAVIKKS5ASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 10.49 µM
dbacp07453 A4K14 - Citropin 1.1 - Sp 3 GLFAVS5KKVS5SVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay C4-2B Prostate Cancer IC50 = 17.89 µM
dbacp07454 A4K14 - Citropin 1.1 - Sp 3 GLFAVS5KKVS5SVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 12.11 µM
dbacp07455 A4K14 - Citropin 1.1 - Sp 3 GLFAVS5KKVS5SVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay U-87 Brain Tumor IC50 = 11.93 µM
dbacp07456 A4K14 - Citropin 1.1 - Sp 3 GLFAVS5KKVS5SVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 11.92 µM
dbacp07457 A4K14 - Citropin 1.1 - Sp 2 GLFAS5IKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay C4-2B Prostate Cancer IC50 = 10.14 µM
dbacp07458 A4K14 - Citropin 1.1 - Sp 2 GLFAS5IKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 12.55 µM
dbacp07459 A4K14 - Citropin 1.1 - Sp 2 GLFAS5IKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay U-87 Brain Tumor IC50 = 14.76 µM
dbacp07460 A4K14 - Citropin 1.1 - Sp 2 GLFAS5IKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 12.65 µM
dbacp07461 A4K14 - Citropin 1.1 - Sp 1 GS5FAVS5KKVASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay C4-2B Prostate Cancer IC50 = 8.94 µM
dbacp07462 A4K14 - Citropin 1.1 - Sp 1 GS5FAVS5KKVASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 12.48 µM
dbacp07463 A4K14 - Citropin 1.1 - Sp 1 GS5FAVS5KKVASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay U-87 Brain Tumor IC50 = 11.88 µM
dbacp07464 A4K14 - Citropin 1.1 - Sp 1 GS5FAVS5KKVASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 11.26 µM
dbacp07465 ΔM4 NFFKRIRRAWKRIWKWIYSA Synthetic Membrane disruption triggers mitochondrial apoptosis Not Available A-375 Skin Cancer IC50 = 9.31 μM
dbacp07477 (LLKK)4 linear peptide LLKKLLKKLLKKLLKK Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay SK-HEP-1 Liver Cancer Cell Viability (%) ~ 14.1 ± 0.8 at 30 µg/mL
dbacp07478 (LLKK)4 linear peptide LLKKLLKKLLKKLLKK Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay HCT-116 Colon Cancer Cell Viability (%) ~ 10.73 ± 2.4 at 30 µg/mL
dbacp07479 (LLKK)4 linear peptide LLKKLLKKLLKKLLKK Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay Bcap-37 Breast Cancer Cell Viability (%) ~ 15.07 ± 0.5 at 30 µg/mL
dbacp07480 (LLKK)4 linear peptide LLKKLLKKLLKKLLKK Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay PC-3 Prostate Cancer Cell Viability (%) ~ 17.1 ± 5.0 at 30 µg/mL
dbacp07481 2-arm branched peptide [LLKKLLKK]2kC Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay SK-HEP-1 Liver Cancer Cell Viability (%) ~ 85.7 ± 4.3 at 30 µg/mL
dbacp07482 2-arm branched peptide [LLKKLLKK]2kC Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay HCT-116 Colon Cancer Cell Viability (%) ~ 78.6 ± 10.5 at 30 µg/mL
dbacp07483 2-arm branched peptide [LLKKLLKK]2kC Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay Bcap-37 Breast Cancer Cell Viability (%) ~ 81.8 ± 8.8 at 30 µg/mL
dbacp07484 2-arm branched peptide [LLKKLLKK]2kC Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay PC-3 Prostate Cancer Cell Viability (%) ~ 73.5 ± 2.2 at 30 µg/mL
dbacp07485 4-arm branched peptide {[LLKKLLKK]2kC}2 Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay SK-HEP-1 Liver Cancer Cell Viability (%) ~ 31.7 ± 5.1 at 30 µg/mL
dbacp07486 4-arm branched peptide {[LLKKLLKK]2kC}2 Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay HCT-116 Colon Cancer Cell Viability (%) ~ 67.6 ± 5.8 at 30 µg/mL
dbacp07487 4-arm branched peptide {[LLKKLLKK]2kC}2 Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay Bcap-37 Breast Cancer Cell Viability (%) ~ 51.4 ± 4.2 at 30 µg/mL
dbacp07488 4-arm branched peptide {[LLKKLLKK]2kC}2 Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay PC-3 Prostate Cancer Cell Viability (%) ~ 49.0 ± 0.8 at 30 µg/mL
dbacp07489 LRH7-G5 Not Available Synthetic GPR1 antagonism, PI3K/AKT inhibition MTT assay MDA-MB-231 Breast Cancer 60% cell viability at 0.01 μM
dbacp07490 LRH7-G5 Not Available Synthetic GPR1 antagonism, PI3K/AKT inhibition MTT assay HCC-1937 Breast Cancer 60% cell viability at 0.1 μM
dbacp07494 RA-3 RWrGGGGGLFDIIKKIAESF Synthetic Integrin-targeting, α-helix mediated lysis MTT assay U87-MG Brain Tumor IC50 = 32.27 μM
dbacp07495 RA-3 RWrGGGGGLFDIIKKIAESF Synthetic Integrin-targeting, α-helix mediated lysis MTT assay MDA-MB-231 Breast Cancer IC50 = 28.4 μM
dbacp07496 RA-3 RWrGGGGGLFDIIKKIAESF Synthetic Integrin-targeting, α-helix mediated lysis MTT assay MCF-7 Breast Cancer IC50 = 44.14 μM
dbacp07497 HX-12A FFRKVLKLIRKI Synthetic derivative of Temporin-Pta ABCB1 inhibition, MDR reversal, sensitization MTT assay KB-C2 Cervical Cancer IC50 = 6.45 μM
dbacp07498 HX-12B FFRKVLKLIRKIF Synthetic derivative of Temporin-Pta ABCB1 inhibition, MDR reversal, sensitization MTT assay KB-C2 Cervical Cancer IC50 = 7.61 μM
dbacp07499 HX-12C FFRKVLKLIRKIWR Synthetic derivative of Temporin-Pta ABCB1 inhibition, MDR reversal, sensitization MTT assay KB-C2 Cervical Cancer IC50 = 6.06 μM
dbacp07509 cyclic dipeptide - 2b WA Synthetic Not Available MTT assay HeLa Cervical Cancer IC50 = 93.1 µM
dbacp07510 cyclic dipeptide - 2b WA Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 45.6 µM
dbacp07517 LL-37 Analogue 2 LKRIVQRIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 33.7 µg/mL
dbacp07518 LL-37 Analogue 3 AKRIVQRIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 29.8 µg/mL
dbacp07519 LL-37 Analogue 4 FΚRIVQRILDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 3.9 µg/mL
dbacp07520 LL-37 Analogue 5 FKSARIVQRILDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 10.7 µg/mL
dbacp07521 LL-37 Analogue 6 FKRIVQRIRDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 56 µg/mL
dbacp07522 LL-37 Analogue 7 FKRIVQRIRDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 12.5 µg/mL
dbacp07523 LL-37 Analogue 8 FKRIVQKIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 145 µg/mL
dbacp07524 LL-37 Analogue 9 FKRIVQLIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 18.9 µg/mL
dbacp07525 LL-37 Analogue 10 FKRIVQLIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 13.9 µg/mL
dbacp07526 LL-37 Analogue 11 FKRIVQRIKDLLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 75 µg/mL
dbacp07527 LL-37 Analogue 12 FKRIVQRIKDLLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 45.5 µg/mL
dbacp07528 LL-37 Analogue 13 FKRIVQIIKKFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 20.0 µg/mL
dbacp07529 LL-37 Analogue 14 FKRIVQIIKKFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 12.9 µg/mL
dbacp07530 LL-37 Analogue 15 FKRIVQLLKKLLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 12.8 µg/mL
dbacp07531 LL-37 Analogue 16 FKRIVQLLKKLLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 9.8 µg/mL
dbacp07532 LL-37 Analogue 17 FKRILQRIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 19.2 µg/mL
dbacp07533 LL-37 Analogue 18 FKRILQRIKDFLR Synthetic Analog of LL-37 Helical peptides disrupt cancer membranes MTT assay A-549 Lung Cancer IC50 = 29.2 µg/mL
dbacp07535 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay CT-26 Colorectal Cancer ~20% cell viability at 10 μg/mL
dbacp07536 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay ID8 Colon Cancer ~60% cell viability at 10 μg/mL
dbacp07537 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay OV-2008 Ovarian Cancer ~60% cell viability at 10 μg/mL
dbacp07538 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay SK-OV-3 Ovarian Cancer ~50% cell viability at 10 μg/mL
dbacp07539 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay CaCo-2 Colon Cancer ~70% cell viability at 10 μg/mL
dbacp07540 HM-10/10 LRKLRKRLLRLVGRQLEEFL Synthetic LPA reduction suppresses tumor growth MTS assay CT-26 Colorectal Cancer ~60% cell viability at 10 μg/mL
dbacp07541 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay CT-26 Colorectal Cancer ~30% cell viability at 10 μg/mL
dbacp07542 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay ID8 Colon Cancer ~20% cell viability at 10 μg/mL
dbacp07543 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay OV-2008 Ovarian Cancer ~40% cell viability at 10 μg/mL
dbacp07544 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay SK-OV-3 Ovarian Cancer ~30% cell viability at 10 μg/mL
dbacp07545 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay CaCo-2 Colon Cancer ~60% cell viability at 10 μg/mL
dbacp07546 Sur-X YGRKKRRQRRRKDHRISTFKNWPFLEGCACTPERM Synthetic Disrupts XIAP-survivin, induces apoptosis/necroptosis MTT assay HCT-116 Colon Cancer 20% cell viability at at 20 μM
dbacp07547 Sur-X YGRKKRRQRRRKDHRISTFKNWPFLEGCACTPERM Synthetic Disrupts XIAP-survivin, induces apoptosis/necroptosis MTT assay HCT-15 Colon Cancer Not Available
dbacp07548 Sur-X YGRKKRRQRRRKDHRISTFKNWPFLEGCACTPERM Synthetic Disrupts XIAP-survivin, induces apoptosis/necroptosis MTT assay RKO Colon Cancer 25% cell viability at at 20 μM
dbacp07549 Sur-X YGRKKRRQRRRKDHRISTFKNWPFLEGCACTPERM Synthetic Disrupts XIAP-survivin, induces apoptosis/necroptosis MTT assay HT-29 Colon Cancer Not Available
dbacp07552 macrocyclic pyridoheptapeptide derivative 1a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 15.329 ± 0.672 μM
dbacp07553 macrocyclic pyridoheptapeptide derivative 1a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 6.615 ± 0.353 μM
dbacp07554 macrocyclic pyridoheptapeptide derivative 1b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 10.904 ± 0.534 μM
dbacp07555 macrocyclic pyridoheptapeptide derivative 1b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 8.724 ± 0.474 μM
dbacp07556 macrocyclic pyridoheptapeptide derivative 1c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 34.894 ± 1.273 μM
dbacp07557 macrocyclic pyridoheptapeptide derivative 1c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 17.011 ± 0.965 μM
dbacp07558 macrocyclic pyridoheptapeptide derivative 2a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 17.513 ± 0.876 μM
dbacp07559 macrocyclic pyridoheptapeptide derivative 2b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 20.697 ± 0.974 μM
dbacp07560 macrocyclic pyridoheptapeptide derivative 2b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 18.681 ± 0.988 μM
dbacp07561 macrocyclic pyridoheptapeptide derivative 2c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 24.943 ± 1.082 μM
dbacp07562 macrocyclic pyridoheptapeptide derivative 2c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 19.318 ± 1.057 μM
dbacp07563 macrocyclic pyridoheptapeptide derivative 3a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 10.316 ± 0.546 μM
dbacp07564 macrocyclic pyridoheptapeptide derivative 3a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 8.063 ± 0.863 μM
dbacp07565 macrocyclic pyridoheptapeptide derivative 3b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 9.911 ± 0.491 μM
dbacp07566 macrocyclic pyridoheptapeptide derivative 3b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 9.66 ± 0.792 μM
dbacp07567 macrocyclic pyridoheptapeptide derivative 3c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 22.864 ± 0.992 μM
dbacp07568 macrocyclic pyridoheptapeptide derivative 3c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 16.957 ± 1.161 μM
dbacp07569 macrocyclic pyridoheptapeptide derivative 4a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 9.304 ± 0.536 μM
dbacp07570 macrocyclic pyridoheptapeptide derivative 4a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 7.31 ± 0.595 μM
dbacp07571 macrocyclic pyridoheptapeptide derivative 4b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 9.188 ± 0.545 μM
dbacp07572 macrocyclic pyridoheptapeptide derivative 4b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 7.166 ± 0.892 μM
dbacp07573 macrocyclic pyridoheptapeptide derivative 4c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 19.552 ± 1.032 μM
dbacp07574 macrocyclic pyridoheptapeptide derivative 4c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 9.631 ± 0.932 μM
dbacp07575 macrocyclic pyridoheptapeptide derivative 5a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 7.117 ± 0.790 μM
dbacp07576 macrocyclic pyridoheptapeptide derivative 5b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 7.088 ± 0.784 μM
dbacp07577 macrocyclic pyridoheptapeptide derivative 5c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 9.568 ± 1.139 μM
dbacp07578 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 125.0 ± 16.8 μM
dbacp07579 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 10.7 ± 0.2 μM
dbacp07580 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 20.9 ± 3.9 μM
dbacp07581 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 4.2 ± 0.2 μM
dbacp07582 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 2.5 ± 0.1 μM
dbacp07583 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.7 ± 0.2 μM
dbacp07584 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 6.3 ± 0.3 μM
dbacp07585 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.0 μM
dbacp07586 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.6 ± 0.1 μM
dbacp07587 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 2.7 ± 0.9 μM
dbacp07588 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.0 μM
dbacp07589 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.6 ± 0.1 μM
dbacp07590 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 6.6 ± 0.3 μM
dbacp07591 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 3.4 ± 0.4 μM
dbacp07592 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 5.0 ± 0.1 μM
dbacp07593 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 < 1 ± 0.1 μM
dbacp07594 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.1 μM
dbacp07595 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 3.6 ± 0.7 μM
dbacp07596 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 4.8 ± 0.4 μM
dbacp07597 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 4.7 ± 0.3 μM
dbacp07598 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 3.8 ± 0.3 μM
dbacp07599 Tritrp-Agb V(Agb)(Agb)FPWWWPFL(Agb)(Agb) Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 9.6 μM
dbacp07600 Tritrp-hArg V(hArg)(hArg)FPWWWPFL(hArg)(hArg) Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 13.3 μM
dbacp07601 Tritrp-Lys VKKFPWWWPFLKK Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 11.5 μM
dbacp07602 Tritrp-Dap V(Dap)(Dap)FPWWWPFL(Dap)(Dap) Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 ≥ 65 μM
dbacp07603 Tritrp-Dab V(Dab)(Dab)FPWWWPFL(Dab)(Dab) Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 ≤ 6.5 μM
dbacp07604 Tritrp-Orn V(Orn)(Orn)FPWWWPFL(Orn)(Orn) Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 ≤ 6.5 μM
dbacp07605 Tritrp-P59A VRRFAWWWAFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 12.5 μM
dbacp07606 Tritrp-P59A-Lys VKKFAWWWAFLKK Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 27.6 μM
dbacp07607 Tritrp-P5A VRRFAWWWPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 16.2 μM
dbacp07608 Tritrp-P5A-Lys VKKFAWWWPFLKK Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 27.6 μM
dbacp07609 Tritrp-P9A VRRFPWWWAFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 6.8 μM
dbacp07610 Tritrp-P9A-Lys VKKFPWWWAFLKK Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 15.1 μM
dbacp07611 Tritrp-W678F VRRFPFFFPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 24.6 μM
dbacp07612 Tritrp-W678bTA VRRFP(bTA)(bTA)(bTA)PFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 9.6 μM
dbacp07613 Tritrp-W6hW VRRFP(hW)WWPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 16.1 μM
dbacp07614 Tritrp-W7hW VRRFPW(hW)WPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 15.1 μM
dbacp07615 Tritrp-W8hW VRRFPWW(hW)PFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 10.7 μM
dbacp07616 Tritrp-W789hW VRRFP(hW)(hW)(hW)PFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 44.8 μM
dbacp07617 Tritrp-W6A VRRFPAWWPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 36.5 μM
dbacp07618 Tritrp-W7A VRRFPWAWPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 48.2 μM
dbacp07619 Tritrp-W8A VRRFPWWAPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 22.8 μM
dbacp07620 Tritrp-W67A VRRFPAAWPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 ≥ 65 μM
dbacp07621 Tritrp-W68A VRRFPAWAPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 ≥ 65 μM
dbacp07622 Tritrp-W78A VRRFPWAAPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 ≥ 65 μM
dbacp07623 Tritrp-W678A VRRFPAAAPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 ≥ 65 μM
dbacp07624 Tritrp-W6Y VRRFPYWWPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 19.3 μM
dbacp07625 Tritrp-W7Y VRRFPWYWPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 11.4 μM
dbacp07626 Tritrp-W8Y VRRFPWWYPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 12.0 μM
dbacp07627 Tritrp-W67Y VRRFPYYWPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 32.2 μM
dbacp07628 Tritrp-W68Y VRRFPYWYPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 35.4 μM
dbacp07629 Tritrp-W78Y VRRFPWYYPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 25.6 μM
dbacp07630 Tritrp-W678Y VRRFPYYYPFLRR Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 ≥ 65 μM
dbacp07631 Tritrp DiSu CVRRFPWWYPFLRRC Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 12.3 μM
dbacp07632 MagaininF5W-Lys GIGKWLHSAKKFGKAFVGEIMNS Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 16.8 μM
dbacp07633 MagaininF5W-Arg GIGRWLHSARRFGRAFVGEIMNS Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 16.8 μM
dbacp07634 PuroA-Arg FPVTWKWWKWWKG Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 10.0 μM
dbacp07635 PuroA-Lys FPVTWRWWRWWRG Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 12.0 μM
dbacp07636 Indolicidin-Lys ILPWKWPWWPWKK Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 9.5 μM
dbacp07637 MPG GALFLGFLGAAGSTMGAWSQPKKKRKV Synthetic Membrane permeabilization via lysine substitution MTT assay Jurkat Blood Cancer IC50 = 15.8 μM
dbacp07638 branched tetrapeptide Schiff bases derivative 4a Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07639 branched tetrapeptide Schiff bases derivative 4b Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07640 branched tetrapeptide Schiff bases derivative 4c Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07641 branched tetrapeptide Schiff bases derivative 5c Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07642 branched tetrapeptide Schiff bases derivative 5d Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07643 branched tetrapeptide Schiff bases derivative 5e Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07668 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.66 ± 0.0007 µg/ml
dbacp07669 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.45 ± 0.0042 µg/ml
dbacp07670 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 13.29% Cell death at 100 µg/ml
dbacp07671 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 83.02% Cell death at 100 µg/ml
dbacp07672 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.2 ± 0.007 µg/ml
dbacp07673 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.4 ± 0.0028 µg/ml
dbacp07674 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 69.73% Cell death at 100 µg/ml
dbacp07675 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 71.5% Cell death at 100 µg/ml
dbacp07676 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 8.76 ± 0.0035 µg/ml
dbacp07677 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.33 ± 0 µg/ml
dbacp07678 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 71.37% Cell death at 100 µg/ml
dbacp07679 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 88.47% Cell death at 100 µg/ml
dbacp07683 Longicalycinin A FYPFG Synthetic Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.45 ± 0.0042 µg/ml
dbacp07684 Longicalycinin A FYPFG Synthetic Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.87 ± 0.0021 µg/ml
dbacp07685 Longicalycinin A (Linear) FYPFG Synthetic Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.18 ± 0.0014 µg/ml
dbacp07686 Longicalycinin A (Linear) FYPFG Synthetic Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.61 ± 0.0007 µg/ml
dbacp07687 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.67 ± 0.0007 µg/ml
dbacp07688 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.12 ± 0.0042 µg/ml
dbacp07689 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 13.02% Cell death at 100 µg/ml
dbacp07690 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 82.36% Cell death at 100 µg/ml
dbacp07691 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.46 ± 0.0028 µg/ml
dbacp07692 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.92 ± 0.0021 µg/ml
dbacp07693 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 70.69% Cell death at 100 µg/ml
dbacp07694 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 52.38% Cell death at 100 µg/ml
dbacp07695 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.77 ± 0.0007 µg/ml
dbacp07696 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.4 ± 0 µg/ml
dbacp07697 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 82.33% Cell death at 100 µg/ml
dbacp07698 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 87.56% Cell death at 100 µg/ml
dbacp07699 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.5 ± 0.0056 µg/ml
dbacp07700 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.28 ± 0.0063 µg/ml
dbacp07701 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 56.72% Cell death at 100 µg/ml
dbacp07702 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 28.51% Cell death at 100 µg/ml
dbacp07703 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.53 ± 0.0014 µg/ml
dbacp07704 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.78 ± 0.0021 µg/ml
dbacp07705 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 27.13% Cell death at 100 µg/ml
dbacp07706 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 75.91% Cell death at 100 µg/ml
dbacp07707 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.77 ± 0.007 µg/ml
dbacp07708 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.33 ± 0.0035 µg/ml
dbacp07709 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 71.1% Cell death at 100 µg/ml
dbacp07710 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 52.49% Cell death at 100 µg/ml
dbacp07711 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 8.99 ± 0.0014 µg/ml
dbacp07712 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.97 ± 0.0049 µg/ml
dbacp07713 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 76.72% Cell death at 100 µg/ml
dbacp07714 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 91.52% Cell death at 100 µg/ml
dbacp07715 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.45 ± 0.0056 µg/ml
dbacp07716 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.98 ± 0.4256 µg/ml
dbacp07717 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 41.37% Cell death at 100 µg/ml
dbacp07718 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 97.74% Cell death at 100 µg/ml
dbacp07719 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.98 ± 0.0014 µg/ml
dbacp07720 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.31 ± 0.0063 µg/ml
dbacp07721 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 38.64% Cell death at 100 µg/ml
dbacp07722 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 49.33% Cell death at 100 µg/ml
dbacp07723 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 17.34 ± 0.0014 µg/ml
dbacp07724 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.2 ± 0.0021 µg/ml
dbacp07725 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 51.79% Cell death at 100 µg/ml
dbacp07726 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 27.61% Cell death at 100 µg/ml
dbacp07727 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.6 ± 0.0007 µg/ml
dbacp07728 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.78 ± 0.0212 µg/ml
dbacp07729 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 82.33% Cell death at 100 µg/ml
dbacp07730 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 84.17% Cell death at 100 µg/ml
dbacp07731 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.21 ± 0.0056 µg/ml
dbacp07732 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.11 ± 0.0035 µg/ml
dbacp07733 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 47.68% Cell death at 100 µg/ml
dbacp07734 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 22.86% Cell death at 100 µg/ml
dbacp07735 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.35 ± 0.0014 µg/ml
dbacp07736 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.88 ± 0.0014 µg/ml
dbacp07737 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.35% Cell death at 100 µg/ml
dbacp07738 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 88.01% Cell death at 100 µg/ml
dbacp07739 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.12 ± 0.0007 µg/ml
dbacp07740 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.67 ± 0.0028 µg/ml
dbacp07741 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 36.85% Cell death at 100 µg/ml
dbacp07742 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 29.87% Cell death at 100 µg/ml
dbacp07743 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.33 ± 0.0007 µg/ml
dbacp07744 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.44 ± 0.5536 µg/ml
dbacp07745 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.74% Cell death at 100 µg/ml
dbacp07746 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 1.59% Cell death at 100 µg/ml
dbacp07747 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.67 ± 0 µg/ml
dbacp07748 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.7 ± 0.0056 µg/ml
dbacp07749 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 73.98% Cell death at 100 µg/ml
dbacp07750 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 76.25% Cell death at 100 µg/ml
dbacp07751 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.5 ± 0.0014 µg/ml
dbacp07752 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.5 ± 0.0007 µg/ml
dbacp07753 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 76.72% Cell death at 100 µg/ml
dbacp07754 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 92.09% Cell death at 100 µg/ml
dbacp07755 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.28 ± 0 µg/ml
dbacp07756 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.56 ± 0.0028 µg/ml
dbacp07757 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.06% Cell death at 100 µg/ml
dbacp07758 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 71.27% Cell death at 100 µg/ml
dbacp07759 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.56 ± 0.0021 µg/ml
dbacp07760 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.67 ± 0.0014 µg/ml
dbacp07761 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 70.28% Cell death at 100 µg/ml
dbacp07762 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 88.47% Cell death at 100 µg/ml
dbacp07763 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.36 ± 0 µg/ml
dbacp07764 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.61 ± 0.0007 µg/ml
dbacp07765 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.06% Cell death at 100 µg/ml
dbacp07766 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 74.89% Cell death at 100 µg/ml
dbacp07767 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 11.32 ± 0.0014 µg/ml
dbacp07768 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 14.2 ± 0.0014 µg/ml
dbacp07769 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 12.06% Cell death at 100 µg/ml
dbacp07770 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 81.34% Cell death at 100 µg/ml
dbacp07771 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 12.37 ± 0.0014 µg/ml
dbacp07772 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 13.2 ± 0 µg/ml
dbacp07773 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 63.84% Cell death at 100 µg/ml
dbacp07774 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 52.72% Cell death at 100 µg/ml
dbacp07775 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.33 ± 0 µg/ml
dbacp07776 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.23 ± 0.0007 µg/ml
dbacp07777 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 52.33% Cell death at 100 µg/ml
dbacp07778 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 27.43% Cell death at 100 µg/ml
dbacp07779 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 11.1 ± 0.0007 µg/ml
dbacp07780 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.11 ± 0.0056 µg/ml
dbacp07781 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.76% Cell death at 100 µg/ml
dbacp07782 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 88.24% Cell death at 100 µg/ml
dbacp07783 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 12.1 ± 0.0007 µg/ml
dbacp07784 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.4 ± 0.0028 µg/ml
dbacp07785 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 42.33% Cell death at 100 µg/ml
dbacp07786 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 29.87% Cell death at 100 µg/ml
dbacp07787 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.33 ± 0.0007 µg/ml
dbacp07788 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.33 ± 0.0035 µg/ml
dbacp07789 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 27.54% Cell death at 100 µg/ml
dbacp07790 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 75.68% Cell death at 100 µg/ml
dbacp07791 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.4 ± 0.0014 µg/ml
dbacp07792 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.2 ± 0.0007 µg/ml
dbacp07793 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 74.53% Cell death at 100 µg/ml
dbacp07794 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 76.14% Cell death at 100 µg/ml
dbacp07795 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.33 ± 0.0007 µg/ml
dbacp07796 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.2 ± 0.0014 µg/ml
dbacp07797 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.55% Cell death at 100 µg/ml
dbacp07798 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 56.51% Cell death at 100 µg/ml
dbacp07799 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.68 ± 0.0014 µg/ml
dbacp07800 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.06 ± 0.0014 µg/ml
dbacp07801 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 46.58% Cell death at 100 µg/ml
dbacp07802 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colon Cancer 22.8% Cell death at 100 µg/ml
dbacp07803 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.3 ± 0.1 µM
dbacp07804 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 1.4 ± 0.1 µM
dbacp07805 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.1 µM
dbacp07806 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 2.7 ± 0.3 µM
dbacp07807 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 2.0 ± 0.1 µM
dbacp07808 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MCF-7 Breast Cancer CC50 = 6.4 ± 0.6 µM
dbacp07809 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 6.7 ± 0.6 µM
dbacp07810 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 4.3 ± 0.3 µM
dbacp07811 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 3.5 ± 0.4 µM
dbacp07812 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 2.5 ± 0.1 µM
dbacp07813 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 13.4 ± 1.9 µM
dbacp07814 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 2.0 ± 0.1 µM
dbacp07815 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.0 ± 0.2 µM
dbacp07816 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 3.9 ± 0.2 µM
dbacp07817 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 18.9 ± 0.9 µM
dbacp07818 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 2.7 ± 0.2 µM
dbacp07819 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 22.5 ± 2.1 µM
dbacp07820 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 17.3 ± 1.0 µM
dbacp07821 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 27.8 ± 2.2 µM
dbacp07822 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 28.2 ± 2.0 µM
dbacp07823 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 13.2 ± 0.9 µM
dbacp07824 [R9S]cT1 KWCFRVCYSGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 5.3 ± 0.6 µM
dbacp07825 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.7 ± 0.1 µM
dbacp07826 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 2.3 ± 0.2 µM
dbacp07827 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.1 µM
dbacp07828 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 3.5 ± 0.3 µM
dbacp07829 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 7.5 ± 0.3 µM
dbacp07830 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.8 ± 0.1 µM
dbacp07831 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 1.2 ± 0.1 µM
dbacp07832 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 1.8 ± 0.1 µM
dbacp07833 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 4.5 ± 0.3 µM
dbacp07834 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 12.2 ± 0.4 µM
dbacp07835 [R9S-R14S-R17S]cT1 KWCFRVCYSGICYSRCSG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 11.8 ± 0.9 µM
dbacp07836 [R9S-R14S-R17S]cT1 KWCFRVCYSGICYSRCSG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 11.1 ± 0.9 µM
dbacp07837 [R9S-R14S-R17S]cT1 KWCFRVCYSGICYSRCSG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 4.8 ± 0.3 µM
dbacp07838 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.0 ± 0.1 µM
dbacp07839 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.2 ± 0.1 µM
dbacp07840 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.2 µM
dbacp07841 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 1.7 ± 0.1 µM
dbacp07842 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 6.7 ± 1.1 µM
dbacp07843 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.3 ± 0.1 µM
dbacp07844 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.2 ± 0.1 µM
dbacp07845 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.9 ± 0.2 µM
dbacp07846 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 1.9 ± 0.1 µM
dbacp07847 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 5.1 ± 0.3 µM
dbacp07854 K8, 23-DPT9 GLWSKIKKAAKTAGKAALGFVNKMV Synthetic Membrane disruption and cationic enhancement MTT assay MCF-7 Breast Cancer IC50 = 8.64 µM
dbacp07855 K8, 23-DPT9 GLWSKIKKAAKTAGKAALGFVNKMV Synthetic Membrane disruption and cationic enhancement MTT assay U251-MG Brain Tumor IC50 = 18.51 µM
dbacp07856 K8, 23-DPT9 GLWSKIKKAAKTAGKAALGFVNKMV Synthetic Membrane disruption and cationic enhancement MTT assay H-157 Lung Cancer IC50 = 9.88 µM
dbacp07857 K8, 23-DPT9 GLWSKIKKAAKTAGKAALGFVNKMV Synthetic Membrane disruption and cationic enhancement MTT assay PC-3 Prostate Cancer IC50 = 9.97 µM
dbacp07858 K8, 23-DPT9 GLWSKIKKAAKTAGKAALGFVNKMV Synthetic Membrane disruption and cationic enhancement MTT assay PANC-1 Pancreatic Cancer IC50 = 11.17 µM
dbacp07882 0Dap GIKKWLHSAKKFGKKFVKKIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 9.1±0.3 μM
dbacp07883 2Dap GIKXWLHSAKKFGXKFVKKIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 14.7±0.6 μM
dbacp07884 4Dap GIKXWLHSAXKFGXKFVKXIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 35.7±0.7 μM
dbacp07885 6Dap GIKXWLHSAXXFGXKFVXXIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 55.0±1.8 μM
dbacp07886 8Dap GIXXWLHSAXXFGXXFVXXIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 61.4±0.7 μM
dbacp07889 H-58 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 0.62 ± 0.12 μM
dbacp07890 H-58 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 1.29 ± 0.08 μM
dbacp07891 H-58 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 2.13 ± 0.07 μM
dbacp07892 H-57 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 0.62 ± 0.12 μM
dbacp07893 H-57 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 1.29 ± 0.08 μM
dbacp07894 H-57 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 2.13 ± 0.07 μM
dbacp07895 H-18 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 0.89 ± 0.21 μM
dbacp07896 H-18 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 1.11 ± 0.21 μM
dbacp07897 H-18 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.61 ± 0.21 μM
dbacp07898 H-21 IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 3.26 ± 0.36 μM
dbacp07899 H-21 IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 3.05 ± 0.21 μM
dbacp07900 H-21 IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.50 ± 0.28 μM
dbacp07901 H-20 IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 2.10 ± 0.32 μM
dbacp07902 H-20 IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 2.63 ± 0.35 μM
dbacp07903 H-20 IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 4.93 ± 0.53 μM
dbacp07904 H-19 IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 1.00 ± 0.36 μM
dbacp07905 H-19 IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 1.78 ± 0.35 μM
dbacp07906 H-19 IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.64 ± 0.36 μM
dbacp07907 H-17 IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 0.96 ± 0.33 μM
dbacp07908 H-17 IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 1.49 ± 0.45 μM
dbacp07909 H-17 IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.64 ± 0.47 μM
dbacp07910 H-16 IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 1.85 ± 0.31 μM
dbacp07911 H-16 IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 2.65 ± 0.35 μM
dbacp07912 H-16 IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 3.14 ± 0.46 μM
dbacp07913 H-15 IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 2.26 ± 0.24 μM
dbacp07914 H-15 IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 2.95 ± 0.25 μM
dbacp07915 H-15 IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 2.20 ± 0.27 μM
dbacp07916 H-10 IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 3.59 ± 0.12 μM
dbacp07917 H-10 IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 3.51 ± 0.37 μM
dbacp07918 H-10 IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.50 ± 0.21 μM
dbacp07919 H-5 IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 7.35 ± 0.22 μM
dbacp07920 H-5 IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 4.16 ± 0.21 μM
dbacp07921 H-5 IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 2.82 ± 0.23 μM
dbacp07922 H-2 IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay A-549 Lung Cancer IC50 = 4.26 ± 0.52 μM
dbacp07923 H-2 IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HCT-116 Colon Cancer IC50 = 3.54 ± 0.72 μM
dbacp07924 H-2 IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.60 ± 0.24 μM
dbacp07934 LyeTx-I-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Membrane disruption, necroptosis, limited apoptosis MTT/Resazurin dye assay U-87-MG Brain Tumor IC50 = 29.20 ± 7.96 µM
dbacp07935 LyeTx-I-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Membrane disruption, necroptosis, limited apoptosis MTT/Resazurin dye assay U-373-MG Brain Tumor IC50 = 20.94 ± 5.18 µM
dbacp07936 LyeTx-I-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Membrane disruption, necroptosis, limited apoptosis MTT/Resazurin dye assay SH-SY5Y Brain Tumor IC50 = 93.80 ± 2.17 µM
dbacp07937 Pantinin-1 GILGKLWEGFKSIV Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 28.5 ± 1.0 µM
dbacp07938 Pantinin-1 GILGKLWEGFKSIV Synthetic Selective binding, membrane disruption, apoptosis MTS assay DU-145 Prostate Cancer IC50 = 47.5 ± 2.0 µM
dbacp07939 Pantinin-2 IFGAIWKGISSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 12.5 ± 1.0 µM
dbacp07940 Pantinin-2 IFGAIWKGISSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay DU-145 Prostate Cancer IC50 = 16.5 ± 1.0 µM
dbacp07941 Pantinin-3 FLSTIWNGIKSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 13.5 ± 2.0 µM
dbacp07942 Pantinin-3 FLSTIWNGIKSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay DU-145 Prostate Cancer IC50 = 17.3 ± 1.0 µM
dbacp07947 IL13Rα2 D1 peptide GSETWKTIITKN Synthetic IL13Rα2 blockade inhibits cancer metastasis MTT assay KM12SM Colorectal Cancer inhibited IL13-stimulated cell adhesion
dbacp07948 IL13Rα2 D1 peptide GSETWKTIITKN Synthetic IL13Rα2 blockade inhibits cancer metastasis MTT assay SW-620 Colorectal Cancer inhibited IL13-stimulated cell adhesion
dbacp07949 IL13Rα2 D1 peptide GSETWKTIITKN Synthetic IL13Rα2 blockade inhibits cancer metastasis MTT assay U-87 Brain Cancer inhibited IL13-stimulated cell adhesion
dbacp07950 IL13Rα2 D1 peptide GSETWKTIITKN Synthetic IL13Rα2 blockade inhibits cancer metastasis MTT assay U-118 Brain Cancer inhibited IL13-stimulated cell adhesion
dbacp07951 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay PC-3 Prostate Cancer IC50 = 792.60 µM
dbacp07952 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay H-157 Lung Cancer IC50 = 58.18 µM
dbacp07953 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay MDA-MB-435S Skin Cancer IC50 = 179.00 µM
dbacp07954 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay U-251-MG Brain Tumor IC50 = 278.30 µM
dbacp07955 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay MCF-7 Breast Cancer IC50 = 316.90 µM
dbacp07956 DP-2 GRKKRRQRRRGALWKSLLKNVGKA Synthetic DRS-DU-1 induces selective tumor cytotoxicity MTT assay H-157 Lung Cancer IC50 = 3.21 μM
dbacp07957 DP-2 GRKKRRQRRRGALWKSLLKNVGKA Synthetic DRS-DU-1 induces selective tumor cytotoxicity MTT assay PC-3 Prostate Cancer IC50 = 6.75 μM
dbacp07958 Compound 2a Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 31.64 ± 1.30 µM
dbacp07959 Compound 2a Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 20.37 ± 1.36 µM
dbacp07960 Compound 2b Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 32.58 ± 1.50 µM
dbacp07961 Compound 2b Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 15.80 ± 1.66 µM
dbacp07962 Compound 2c Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 35.52 ± 1.83 µM
dbacp07963 Compound 3a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 26.01 ± 2.35 µM
dbacp07964 Compound 3b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 25.33 ± 1.18 µM
dbacp07965 Compound 3b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 13.54 ± 1.45 µM
dbacp07966 Compound 3c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 29.55 ± 2.06 µM
dbacp07967 Compound 3c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 26.64 ± 1.85 µM
dbacp07968 Compound 4a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 11.59 ± 2.70 µM
dbacp07969 Compound 4b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 10.45 ± 1.33 µM
dbacp07970 Compound 4b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 10.25 ± 2.20 µM
dbacp07971 Compound 4c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 29.15 ± 1.39 µM
dbacp07972 Compound 4c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 18.84 ± 1.47 µM
dbacp07973 Compound 5a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 12.67 ± 2.40 µM
dbacp07974 Compound 5a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 11.19 ± 1.95 µM
dbacp07975 Compound 5b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 11.32 ± 1.15 µM
dbacp07976 Compound 5b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 10.09 ± 2.05 µM
dbacp07977 Compound 5c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 9.41 ± 1.25 µM
dbacp07978 Compound 5c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 7.53 ± 1.33 µM
dbacp07979 Compound 6a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 11.83 ± 1.62 µM
dbacp07980 Compound 6a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 12.44 ± 1.3 µM
dbacp07981 Compound 6b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 10.87 ± 1.10 µM
dbacp07982 Compound 6b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 11.53 ± 1.70 µM
dbacp07983 Compound 6c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 12.07 ± 1.68 µM
dbacp07984 SOR-C13 KEFLHPSKVDLPR Synthetic TRPV6 inhibition suppresses ovarian tumors IP SKOV-3 Ovarian Cancer Effectively inhibited the growth of tumor
dbacp07986 SmacN7-Arg8 fused peptide P4 Ahx-AVPIAQK(KRRRRRRRRRE) Synthetic Apoptosis inducing Cell Titer Blue Cell Viability assay U-266 Skin Cancer Cell viability < 50% at 50 μM
dbacp07987 SmacN7-Arg8 fused peptide P5 Ahx-(KAVPIAQKE)RRRRRRRR Synthetic Apoptosis inducing Cell Titer Blue Cell Viability assay U-266 Skin Cancer Cell viability < 50% at 50 μM
dbacp07988 SmacN7-Arg8 fused peptide P7 Ahx-(KAVPIAQKE)GG(KRRRRRRRRE) Synthetic Apoptosis inducing Cell Titer Blue Cell Viability assay U-266 Skin Cancer Cell viability < 50% at 50 μM
dbacp07993 [G10a]SHa FLSGIVGMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 16.2 ± 2.2 µM
dbacp07994 [G10a]SHa FLSGIVGMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 = 22.7 ± 0.86 µM
dbacp07995 [G10a]SHa FLSGIVGMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 =24.3 ± 0.8 µM
dbacp07996 [G10a]SHa-BCTP FLSGIVGMLaKLFLFKQYAELW Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 26.85 ± 1.85 µM
dbacp07997 [G10a]SHa-BCTP FLSGIVGMLaKLFLFKQYAELW Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp07998 [G10a]SHa-BCTP FLSGIVGMLaKLFLFKQYAELW Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp07999 [G4a]SHa FLSaIVGMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 17.9 ± 1.1 µM
dbacp08000 [G4a]SHa FLSaIVGMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08001 [G4a]SHa FLSaIVGMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp08002 [G7a]SHa FLSGIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 =22.4 ± 2.2 µM
dbacp08003 [G7a]SHa FLSGIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08004 [G7a]SHa FLSGIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp08005 [G4,7a]SHa FLSaIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 29.5 ± 6.03 µM
dbacp08006 [G4,7a]SHa FLSaIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08007 [G4,7a]SHa FLSaIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 = 37.3 ± 3.5 µM
dbacp08008 [G4,7,10a]SHa FLSaIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 26.33 ± 5.8 µM
dbacp08009 [G4,7,10a]SHa FLSaIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08010 [G4,7,10a]SHa FLSaIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp08011 [G7,10a]SHa FLSGIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 21.3 ± 1.13 µM
dbacp08012 [G7,10a]SHa FLSGIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08013 [G7,10a]SHa FLSGIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp08014 Ec-LDP-hBD1 MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH Synthetic EGFR-targeted defensin induces mitochondrial apoptosis CCK-8 assay A-431 Skin Cancer IC50 = 1.8 μM
dbacp08015 Ec-LDP-hBD1 MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH Synthetic EGFR-targeted defensin induces mitochondrial apoptosis CCK-8 assay A-549 Lung Cancer IC50 = 11.9 μM
dbacp08016 Ec-LDP-hBD1 MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH Synthetic EGFR-targeted defensin induces mitochondrial apoptosis CCK-8 assay H-460 Lung Cancer IC50 = 5.19 μM
dbacp08017 Ec-LDP-hBD1 MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH Synthetic EGFR-targeted defensin induces mitochondrial apoptosis CCK-8 assay PG-BE1 Lung Cancer IC50 = 31.3 μM
dbacp08045 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay B-16 Skin Cancer ED50 = 7.1 μM
dbacp08046 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay PANC-1 Pancreatic Cancer ED50 = 7.8 μM
dbacp08047 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay HepG-2 Liver Cancer ED50 = 5.9 μM
dbacp08048 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay MDA-MD-231 Breast Cancer ED50 = 5.6 μM
dbacp08049 Temporin-1Ga SILPTIVSFLSKVF Synthetic Temporin-1OLa disrupts bacterial membranes MTS assay 4T1 Breast Cancer LC50 = 20 μM
dbacp08050 Temporin-CPa IPPFIKKVLTTVF Synthetic Temporin-1OLa disrupts bacterial membranes MTS assay 4T1 Breast Cancer LC50 = 80 μM
dbacp08051 MEL-Pep GIGAVLKKLTTGLKALISWIKRKRQQ Synthetic analog of Melittin MEL-pep disrupts membrane, inhibits P-gp CCK-8 assay BEL-7402/5-FU Liver Cancer IC50 = 4.36 μM
dbacp08055 L-FP21-PEG-PEI/pGRO-α YTRDLVYGDPARPGIQGTGTF Synthetic D-FP21 delivers gene, inhibits proliferation CCK-8 assay HO-8910 Ovarian Cancer IC50 = 23.4 μg/mL
dbacp08056 D-FP21-PEG-PEI/pGRO-α ytrdlvygdparpgiqgtgtf Synthetic D-FP21 delivers gene, inhibits proliferation CCK-8 assay HO-8910 Ovarian Cancer IC50 = 21.6 μg/mL
dbacp08057 TAK-448 ywNTF(AzGly)R(Me)W Synthetic TAK-448 reduces testosterone, inhibits tumor Given i.h. VCaP Prostate Cancer Had greater anti-tumor effects in VCaP xenograft model
dbacp08063 E5 GGRSFFLLRRIQGCRFRNTVDD Synthetic E5 inhibits CXCR4–CXCL12 signaling CCK-8 assay 4T1 Breast Cancer 49% cell viability at 100 μM
dbacp08068 temporin-PEa FLYIVAKLLSGLL Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay NCI-H-157 Lung Cancer IC50 = 3.398 μM
dbacp08069 temporin-PEa FLYIVAKLLSGLL Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay U251-MG Brain Tumor IC50 = 3.520 μM
dbacp08070 temporin-PEa FLYIVAKLLSGLL Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay PC-3 Prostate Cancer IC50 = 27.62 μM
dbacp08071 temporin-PEa FLYIVAKLLSGLL Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay MDA-MB-435S Skin Cancer IC50 = 9.864 μM
dbacp08072 temporin-PEb FLPIVAKLLSGLLGRKKRRQRRR Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay NCI-H-157 Lung Cancer IC50 = 3.464 μM
dbacp08073 temporin-PEb FLPIVAKLLSGLLGRKKRRQRRR Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay U251-MG Brain Tumor IC50 = 3.087 μM
dbacp08074 temporin-PEb FLPIVAKLLSGLLGRKKRRQRRR Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay PC-3 Prostate Cancer IC50 = 3.051 μM
dbacp08075 temporin-PEb FLPIVAKLLSGLLGRKKRRQRRR Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay MDA-MB-435S Skin Cancer IC50 = 3.483 μM
dbacp08081 Peptide 3a YD Synthetic Inhibit COX-2 enzyme MTT assay MCF-7 Breast Cancer IC50 = 17.5 ± 0.04 µM
dbacp08082 Peptide 3a YD Synthetic Inhibit COX-2 enzyme MTT assay HepG-2 Liver Cancer IC50 = 4.8 ± 0.12 µM
dbacp08083 Peptide 3a YD Synthetic Inhibit COX-2 enzyme MTT assay A-549 Lung Cancer IC50 = 5.7 ± 0.04 µM
dbacp08084 Peptide 3b YD Synthetic Inhibit COX-2 enzyme MTT assay HepG-2 Liver Cancer IC50 = 62.3 ± 0.02 µM
dbacp08085 Peptide 3b YD Synthetic Inhibit COX-2 enzyme MTT assay A-549 Lung Cancer IC50 = 5.8 ± 0.02 µM
dbacp08112 FR-15 FRRFFKWFRRFFKFF Synthetic Proline-substituted AMP triggers mitochondrial apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 3.15 μM
dbacp08113 FR-15 FRRFFKWFRRFFKFF Synthetic Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HeLa Cervical Cancer IC50 = 4.9 μM
dbacp08114 FR-15 FRRFFKWFRRFFKFF Synthetic Proline-substituted AMP triggers mitochondrial apoptosis MTT assay DLD-1 Colon Cancer IC50 = 6.7 μM
dbacp08115 FR-15 FRRFFKWFRRFFKFF Synthetic Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HepG-2 Liver Cancer IC50 = 2.5 μM
dbacp08143 MccJ25-18-4 GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL Synthetic Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 14.2 ± 1.5 μM
dbacp08144 MccJ25-18-4 GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL Synthetic Apoptosis inducing MTT assay MDA-MB-435 Breast Cancer IC50 = 20.0 ± 0.5 μM
dbacp08145 MccJ25-18-4 GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL Synthetic Apoptosis inducing MTT assay MDA-MB-435-MDR Breast Cancer IC50 = 25.0 ± 0.5 μM
dbacp08146 LfcinB-P13 KCRRWLKRMKKLG Synthetic analog of LFcinB LfcinB-P13 induces liver cancer apoptosis MTT assay SMMC-7721 Liver Cancer IC50 = 41.8 µg/ml
dbacp08150 CIGB-552 HARIKpTFRRlKWKYKGKFW Synthetic Not Available Sulforhodamine B assay MCF-7 Breast Cancer IC50 = 379.1 ± 8.6 µM
dbacp08151 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 40% LDH release at 32 μM
dbacp08152 IL-1 FKAGGFIKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 73.9 ± 13.6 μM
dbacp08153 IL-1 FKAGGFIKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay PC-3 Prostate Cancer IC50 = 58.4 ± 13.7 μM
dbacp08154 IL-1 FKAGGFIKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 30% LDH release at 32 μM
dbacp08155 IL-2 FKIGGFAKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 52.0 ± 5.8 μM
dbacp08156 IL-2 FKIGGFAKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay PC-3 Prostate Cancer IC50 = 43.6 ± 7.9 μM
dbacp08157 IL-2 FKIGGFAKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 30% LDH release at 32 μM
dbacp08158 IL-3 FKIGGFIKKAWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 93.5 ± 19.4 μM
dbacp08159 IL-3 FKIGGFIKKAWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay PC-3 Prostate Cancer IC50 = 74.9 ± 13.3 μM
dbacp08160 IL-3 FKIGGFIKKAWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 35% LDH release at 32 μM
dbacp08161 IL-4 FKIGGFIKKLWRSALA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 54.4 ± 3.0 μM
dbacp08162 IL-4 FKIGGFIKKLWRSALA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay PC-3 Prostate Cancer IC50 = 35.5 ± 3.9 μM
dbacp08163 IL-4 FKIGGFIKKLWRSALA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 28% LDH release at 32 μM
dbacp08164 IL-5 FKIGGFIKKLWRSLAA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 28.0 ± 4.6 μM
dbacp08165 IL-5 FKIGGFIKKLWRSLAA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay PC-3 Prostate Cancer IC50 = 22.0 ± 2.6 μM
dbacp08166 IL-5 FKIGGFIKKLWRSLAA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 35% LDH release at 32 μM
dbacp08169 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08170 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 6.2 µM
dbacp08171 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08172 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 5.4 µM
dbacp08173 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08174 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 2.6 µM
dbacp08175 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 = 7.3 µM
dbacp08176 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 3.0 µM
dbacp08177 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay PC-3 Prostate Cancer Not Available
dbacp08178 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay A-549 Lung Cancer Not Available
dbacp08179 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay NCI-H69 Lung Cancer Not Available
dbacp08180 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay RL Lymphoma Cancer Not Available
dbacp08181 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 = 2.6 µM
dbacp08182 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 7.0 µM
dbacp08183 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 = 6.0 µM
dbacp08184 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 6.6 µM
dbacp08185 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 = 6.4 µM
dbacp08186 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 6.4 µM
dbacp08187 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 = 5.0 µM
dbacp08188 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 5.6 µM
dbacp08189 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 = 5.9 µM
dbacp08190 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 4.6 µM
dbacp08191 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 = 5.4 µM
dbacp08192 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 3.2 µM
dbacp08193 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 = 6.2 µM
dbacp08194 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 3.1 µM
dbacp08195 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 = 3.6 µM
dbacp08196 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 4.7 µM
dbacp08197 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 = 2.7 µM
dbacp08198 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 3.0 µM
dbacp08199 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 = 2.3 µM
dbacp08200 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 6.4 µM
dbacp08201 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 = 2.6 µM
dbacp08202 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 1.9 µM
dbacp08203 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 = 4.4 µM
dbacp08204 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 2.1 µM
dbacp08205 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08206 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08207 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08208 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08209 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08210 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08211 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08212 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08213 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08214 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08215 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08216 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08217 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08218 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08219 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08220 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08221 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08222 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08223 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08224 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08225 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08226 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08227 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08228 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08229 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08230 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08231 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08232 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08233 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08234 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08235 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08236 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08237 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08238 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08239 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08240 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08241 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08242 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08243 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08244 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08245 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08246 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 7.3 µM
dbacp08247 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08248 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 6.7 µM
dbacp08249 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08250 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 6.4 µM
dbacp08251 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08252 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 4.2 µM
dbacp08266 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay HeLa Cervical Cancer IC50 = 8.1 ± 1.6 μM
dbacp08267 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay SACC-83 Salivary Cancer IC50 = 9.9 ± 1.7 μM
dbacp08268 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 7.5 ± 1.2 μM
dbacp08269 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay Huh-7 Liver Cancer IC50 = 8.4 ± 1.1 μM
dbacp08270 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay PC-3 Prostate Cancer IC50 = 14.2 ± 0.5 μM
dbacp08271 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay 293T Kidney Cancer IC50 = 6.3 ± 0.7 μM
dbacp08291 L-Carnosine Beta-AH Synthetic Not Available MTT assay A-2780 Ovarian Cancer IC50 = 165 mM
dbacp08292 L-Carnosine Beta-AH Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 125 mM
dbacp08293 L-Carnosine Beta-AH Synthetic Not Available MTT assay SK-OV-3 Ovarian Cancer IC50 = 485 mM
dbacp08294 CA4 CGPCFTTDHNMARKCDECCGGKGRGKCFGPQCLCR Synthetic Not Available MTT assay U-251 Brain Tumor Graph Figure 2
dbacp08295 CTX-23 VCMPCFTTDQQMARKCSDCCGGKGRGKCYGPQCLCR Synthetic Not Available MTT assay U-251 Brain Tumor Graph Figure 2
dbacp08297 DN1 ILGKIVKKLVSDF Synthetic Not Available MTT assay HepG-2 Liver Cancer 152.17 ± 7.73 μM
dbacp08298 DN4 ILGKIWKGIVSDF Synthetic Not Available MTT assay HepG-2 Liver Cancer 191.67 ± 12.02 μM
dbacp08299 SKACP003 FPLPCAYKGTYC Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 193 ± 0.5 µM
dbacp08300 SKACP003 FPLPCAYKGTYC Synthetic Not Available MTT assay MDA-MB-231 Breast Cancer IC50 = 212 ± 0.5 µM
dbacp08301 SKACP003 FPLPCAYKGTYC Synthetic Not Available MTT assay MDA-MB-453 Breast Cancer IC50 = 156 ± 0.5 µM
dbacp08303 ATRA1-R3W2 - HYD RRWKRFFKRWKGGVIGVTFPF Synthetic Not Available Cytotoxicity assay H-358 Lung Cancer LD50 ~24.5 μM
dbacp08304 MAD1 KRWHWWRRHWVVW Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 14.2 μM
dbacp08305 MAD1 KRWHWWRRHWVVW Synthetic Not Available MTT assay A-549 Lung Cancer IC50 = 36.2 μM
dbacp08306 MAD1 KRWHWWRRHWVVW Synthetic Not Available MTT assay NCI/ADR-RES Ovarian Cancer IC50 = 85.6 μM
dbacp08307 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay A-549 Lung Cancer IC50 = 11.9 μM
dbacp08308 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 8.6 μM
dbacp08309 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay NCI/ADR-RES Ovarian Cancer IC50 = 14.0 μM
dbacp08310 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay T-24 Bladder Cancer IC50 = 15.3 μM
dbacp08311 AMP1 WKWLKKWIK Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 51.1 μM
dbacp08312 AMP2 KRWWKWWRR Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 53.5 μM
dbacp08313 P1C YKSIEFC Synthetic Not Available Cell Proliferation assay BXPC-3 Pancreatic Cancer ~40% reduction in cell growth at 20 μM
dbacp08314 P1A YKSIEFC Synthetic Not Available Cell Proliferation assay BXPC-4 Pancreatic Cancer ~50% reduction in cell growth at 20 μM
dbacp08315 P1B YKSVEFC Synthetic Not Available Cell Proliferation assay BXPC-5 Pancreatic Cancer ~50% reduction in cell growth at 20 μM
dbacp08316 Sample Peptide 1 from US011339203B2 LTSVVFILICCFHLENIFVLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 48% at 25 μM
dbacp08317 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 0.4% at 25 μM
dbacp08318 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay PC-3 Prostate Cancer Cell Viability = 2.5% at 25 μM
dbacp08319 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay A-2058 Skin Cancer Cell Viability = 0.2% at 25 μM
dbacp08320 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay NCI-H2444 Lung Cancer Cell Viability = 0.6% at 25 μM
dbacp08321 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay A-549 Lung Cancer Cell Viability = 1.4% at 25 μM
dbacp08322 Sample Peptide 3 from US011339203B2 WFLREGSMFVALSASVFSLLAIKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 45.8% at 25 μM
dbacp08323 Sample Peptide 4 from US011339203B2 FLLISACWVISLILGGLPIMGWKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 85.6% at 25 μM
dbacp08324 Sample Peptide 5 from US011339203B2 LYHKHYILECTTVFTLLLLSIVILYCRIKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 77.6% at 25 μM
dbacp08325 Sample Peptide 6 from US011339203B2 VIIVLSVFIACWAPLFILLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 59.7% at 25 μM
dbacp08326 Sample Peptide 7 from US011339203B2 LFRAEYFLVLAVLNSGTNPIIKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 66.3% at 25 μM
dbacp08327 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 NCI-H2444 Lung Cancer Cell Viability = 6.8% at 25 μM
dbacp08328 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 11.8% at 25 μM
dbacp08329 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 NCI-H446 Lung Cancer Cell Viability = 0.5% at 25 μM
dbacp08330 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 A-2058 Skin Cancer Cell Viability = 6.7% at 25 μM
dbacp08331 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 MDA-MB-231 Breast Cancer Cell Viability = 62.3% at 25 μM
dbacp08332 Sample Peptide 2 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRRKKRRQRRR Synthetic Not Available CCK-8 / WST-8 NCI-H2444 Lung Cancer Cell Viability = 3.6% at 25 μM
dbacp08333 Sample Peptide 2 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRRKKRRQRRR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 4.9% at 25 μM
dbacp08334 Sample Peptide 2 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRRKKRRQRRR Synthetic Not Available CCK-8 / WST-8 A-549 Lung Cancer Cell Viability = 9.1% at 25 μM
dbacp08335 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 NCI-H2444 Lung Cancer Cell Viability = 87.7% at 25 μM
dbacp08336 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 120.6% at 25 μM
dbacp08337 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 NCI-H446 Lung Cancer Cell Viability = 56.7% at 25 μM
dbacp08338 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 A-2058 Skin Cancer Cell Viability = 87.5% at 25 μM
dbacp08339 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 MDA-MB-231 Breast Cancer Cell Viability = 81.7% at 25 μM
dbacp08340 Sample Peptide 4 from EP3604345B1 PWWWPPVVVQQQMILLIGAARKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 102.6% at 25 μM
dbacp08341 Sample Peptide 5 from EP3604345B1 KKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 106.5% at 25 μM
dbacp08349 LPSBD-0 CQYSVNPKIKRFELYFKGRMW Synthetic Not Available Not Available THP-1 Leukemia Cancer Not Available
dbacp08350 LPSBD-2 CHYRVKPKIKRFEKYKGRMW Synthetic Not Available Not Available THP-1 Leukemia Cancer Not Available
dbacp08351 Seq ID No. 15 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVTSVIK Synthetic Not Available Tetrazolium-based assay HOP-062 Lung Cancer Cell viability ~ 50% at 20 μM
dbacp08352 Seq ID No. 15 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVTSVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability < 25% at 20 μM
dbacp08353 Seq ID No. 15 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVTSVIK Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability < 50% at 20 μM
dbacp08354 Seq ID No. 16 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKSVIK Synthetic Not Available Tetrazolium-based assay HOP-062 Lung Cancer Cell viability > 50% at 20 μM
dbacp08355 Seq ID No. 16 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKSVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability > 50% at 20 μM
dbacp08356 Seq ID No. 16 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKSVIK Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability > 50% at 20 μM
dbacp08357 Seq ID No. 17 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKKVIK Synthetic Not Available Tetrazolium-based assay HOP-062 Lung Cancer Cell viability > 50% at 20 μM
dbacp08358 Seq ID No. 17 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKKVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability > 50% at 20 μM
dbacp08359 Seq ID No. 17 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKKVIK Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability > 50% at 20 μM
dbacp08360 Seq ID No. 26 from patent ID US202000079827A1 RRWVRRVRRVWRRVVRVVRRWVRR Synthetic Not Available Tetrazolium-based assay H-460 Lung Cancer Cell viability < 50% at 20 μM
dbacp08361 Seq ID No. 26 from patent ID US202000079827A1 RRWVRRVRRVWRRVVRVVRRWVRR Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability > 50% at 20 μM
dbacp08362 Seq ID No. 34 from patent ID US202000079827A1 RRWvRRvRRvWRRvvRvvRRWvRR Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability < 25% at 20 μM
dbacp08363 Seq ID No. 34 from patent ID US202000079827A1 RRWvRRvRRvWRRvvRvvRRWvRR Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability > 50% at 20 μM
dbacp08364 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay RG1 Glioblastoma EC50 ~ 7 μM
dbacp08365 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay GMB-27 Glioblastoma EC50 ~ 7.5 μM
dbacp08366 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay 12015 Glioblastoma EC50 ~ 10 μM
dbacp08367 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay 12089 Glioblastoma EC50 ~ 4 μM
dbacp08368 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay RG6 Glioblastoma EC50 ~ 5 μM
dbacp08369 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay RG4 Glioblastoma EC50 ~ 5 μM
dbacp08370 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay RG5 Glioblastoma EC50 ~ 7 μM
dbacp08371 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay 12053 Glioblastoma EC50 ~ 50 μM
dbacp08372 IDP-NS02 RQRRNDLRSSFLTLRDH Synthetic Not Available AlamarBlue assay NCI-H524 Lung Cancer EC50 ~ 5 μM
dbacp08373 IDP-NS16 RQRRNDLRSSFLTLRDH Synthetic Not Available AlamarBlue assay RG1 Glioblastoma EC50 ~ 15 μM
dbacp08374 IDP-NS16 RQRRNDLRSSFLTLRDH Synthetic Not Available AlamarBlue assay 12053 Glioblastoma EC50 ~ 10 μM
dbacp08375 IDP-Na05 RRNDLRSSFLTLRDHVP Synthetic Not Available AlamarBlue assay RG1 Glioblastoma EC50 ~ 10 μM
dbacp08376 IDP-NLCa02 RQIKIWFQNRRMKWKKRQRRNDLRSSFLTLRDHVP Synthetic Not Available AlamarBlue assay RG1 Glioblastoma EC50 ~ 5 μM
dbacp08377 IDP-wtL05 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 10 μM
dbacp08378 IDP-LS05 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test HL-60 Leukemia Cancer EC50 ~ 5 μM
dbacp08379 IDP-LS05 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 6 μM
dbacp08380 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test MCF-7 Breast Cancer EC50 ~ 10 μM
dbacp08381 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test HL-60 Leukemia Cancer EC50 ~ 7 μM
dbacp08382 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 9 μM
dbacp08383 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test U266 Lymphoma Cancer EC50 ~ 10 μM
dbacp08384 IDP-LS15 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 7 μM
dbacp08385 IDP-LS15 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test U266 Lymphoma Cancer EC50 ~ 8 μM
dbacp08386 IDP-LS16 APKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 15 μM
dbacp08387 IDP-LS16 APKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test U266 Lymphoma Cancer EC50 ~ 10 μM
dbacp08388 IDP-LS17 APKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 10 μM
dbacp08389 IDP-LS17 APKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test U266 Lymphoma Cancer EC50 ~ 16 μM
dbacp08390 IDP-LLCb01 RRRRRRRSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 5 μM
dbacp08391 IDP-LLCb01 RRRRRRRSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 2.5 μM
dbacp08392 IDP-LLCb01 RRRRRRRSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 5 μM
dbacp08393 IDP-LLCb02 RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 7.5 μM
dbacp08394 IDP-LLCb02 RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 10 μM
dbacp08395 IDP-LLCb02 RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 15 μM
dbacp08396 IDP-Lb01 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 22.5 μM
dbacp08397 IDP-Lb01 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 12.5 μM
dbacp08398 IDP-Lb01 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 22.5 μM
dbacp08399 IDP-Lb02 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 22.5 μM
dbacp08400 IDP-Lb02 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 7.5 μM
dbacp08401 IDP-Lb02 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 15 μM
dbacp08402 IDP-Lb03 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 22.5 μM
dbacp08403 IDP-Lb03 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 5 μM
dbacp08404 IDP-Lb03 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 15 μM
dbacp08405 IDP-Lb04 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 > 30 μM
dbacp08406 IDP-Lb04 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 12.5 μM
dbacp08407 IDP-Lb04 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 > 30 μM
dbacp08408 IDP-Lb05 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 10 μM
dbacp08409 IDP-Lb05 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 7.5 μM
dbacp08410 IDP-Lb05 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 12.5 μM
dbacp08411 IDP-Lb06 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 12.5 μM
dbacp08412 IDP-Lb06 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 7.5 μM
dbacp08413 IDP-Lb06 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 12.5 μM
dbacp08414 IDP-La05 RRNDLRSRFLALRDQVP Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 22.5 μM
dbacp08415 IDP-La05 RRNDLRSRFLALRDQVP Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 15 μM
dbacp08416 IDP-La05 RRNDLRSRFLALRDQVP Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 10 μM
dbacp08417 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay U343 Glioblastoma IC50 = 0.781 μM
dbacp08418 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay U373MG Glioblastoma IC50 = 0.8717 μM
dbacp08419 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay U251 Glioblastoma IC50 = 0.7607 μM
dbacp08420 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay U87-MG Glioblastoma IC50 = 0.9164 μM
dbacp08421 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 3.064 μM
dbacp08422 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay Hep3B Liver Cancer IC50 = 0.7847 μM
dbacp08423 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay 293T Renal Cancer IC50 = 1.107 μM
dbacp08424 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 9.74 μM
dbacp08425 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay MDA-MB-231 Breast Cancer IC50 = 0.8061 μM
dbacp08426 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay HL-60 Blood Cancer IC50 = 1.111 μM
dbacp08427 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay K-562 Blood Cancer IC50 = 1.103 μM
dbacp08428 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay Hel Blood Cancer IC50 = 1.055 μM
dbacp08429 hBD3-3 M1 GKCSTRGRKCMRRKK Synthetic Not Available Cell Proliferation assay MDA-MB-231 Breast Cancer Concentration dependent reduction in colony formation between 100 μM and 200 μM.
dbacp08430 hBD3-3 M1 GKCSTRGRKCMRRKK Synthetic Not Available Annexin V/ PI staining assay MDA-MB-231 Breast Cancer Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group
dbacp08431 hBD3-3 M2 GKCSTRGRKMCRRKK Synthetic Not Available Cell Proliferation assay MDA-MB-231 Breast Cancer Concentration dependent reduction in colony formation between 100 μM and 200 μM.
dbacp08432 hBD3-3 M2 GKCSTRGRKMCRRKK Synthetic Not Available Annexin V/ PI staining assay MDA-MB-231 Breast Cancer Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group
dbacp08433 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available MTT assay A-549 Lung Cancer 9.4% growth inhibition at 70 μg/mL
dbacp08434 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available MTT assay NCI-H1975 Lung Cancer 36.3% growth inhibition at 70 μg/mL
dbacp08435 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available MTT assay PANC-1 Pancreatic Cancer 26.2% growth inhibition at 70 μg/mL
dbacp08436 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available TUNEL assay A-549 Lung Cancer Mean apoptotic rate = 36% at 200 μg/mL
dbacp08437 Balixafortide ACSAp(Dab)RYCYQKpPYH Synthetic Not Available HUVEC sprouting Namalwa Lymphoma IC50< 10 nM
dbacp08438 Balixafortide ACSAp(Dab)RYCYQKpPYH Synthetic Not Available HUVEC sprouting Jurkat Blood Cancer IC50< 10 nM
dbacp08439 Balixafortide ACSAp(Dab)RYCYQKpPYH Synthetic Not Available HUVEC sprouting MDA-MB-231 Breast Cancer IC50< 20 nM